Drug, bio-affecting and body treating compositions inventions 03/06

20060067879 - Diagnosis of diseases associated with cox-2 expression: Derivatives of cyclooxygenase-2 inhibitor compounds are made incorporating a label that can be identified upon administration into the body of a mammal and subsequent binding of the compounds with cyclooxygenase-2 that is overexpressed due to a disease condition such as cancer....

20060067880 - Labeled creatine ethyl ester hydrochloride: The present invention relates to various radiolabeled creatine ethyl ester hydrochloride compounds. Any carbon, hydrogen or nitrogen atom of the compounds may be radiolabeled using 14C, 13C, 2H, 3H or 15N atoms....

20060067881 - Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products: Stable isotope labeling and neutron activation to measure biological functions are provided, as are the use and method of adding a chemical monitor to correct for neutron flux to sample vials prior to the addition of sample is presented, and the use of stable isotopes as a chemical bar code...

20060067882 - Polymeric-matrix brachytherapy sources: Therapeutic sources for use in the practice of brachytherapy comprise a radioactive composite that includes (a) a polymeric matrix and (b) a radioactive powder, e.g. Pd-103 or I-125, consisting essentially of very fine radioactive particles that are randomly and essentially uniformly dispersed within the polymeric matrix. The composite may be...

20060067883 - Microspheres capable of binding radioisotopes, optionally comprising metallic microparticles, and methods of use thereof: One aspect of the present invention relates to a microsphere, comprising a hydrophilic polymer comprising a plurality of pendant anionic groups; a transition-metal, lanthanide or group 13-14 metal oxide, polyoxometalate or metal hydroxide or combination thereof; and a first radioisotope that emits a therapeutic β-particle. In certain embodiments, the microsphere...

20060067885 - Method and kit for imaging and treating organs and tissues: Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody/fragment which specifically...

20060067884 - Method for radiolabeling antibodies with yttrium-90: Methods and kits for radiolabeling proteins, peptides and ligands with radiolytic isotopes, particularly yttrium-90, are disclosed, whereby sufficient purity, specific activity and binding affinity are achieved such that the radiolabeled protein may be directly administered to a patient without further column purification. Such kits and methods will be particularly useful...

20060067886 - Gastrin receptor-avid peptide conjugates: A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject...

20060067887 - Scoring estrogen and progesterone receptors expression based on image analysis: A method of scoring Oestrogen and Progesterone Receptors expression (ER and PR) from histological images determines the percentage of brown image blob area in total blob area and derives percentage thresholds to quantify scoring. Brown blob area proportion is then compared with the thresholds to provide a first contribution to...

20060067888 - Immunogenic glycopeptides, screening, preparation and uses: The invention relates to immunogenic glycopeptides derived from pathogenic microorganisms, which can be used for immunization and diagnosing infections dye to such pathogenic microorganisms and also to method for the selection and preparation thereof....

20060067889 - Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted pdt agents: Provided herein are conjugates, kits, articles of manufacture and methods for detection, diagnosis and treatment by photodynamic therapy of certain undesired biological substrate targets, including, but not limited to bacteria, viruses, and other pathogenic microorganisms, tumors and hyperproliferative tissue. In particular, the conjugates provided include a fluorophore or photosensitizer linked...

20060067890 - Telomelysin/gfp-expressing recombinant virus: The present invention provides a reagent for cancer cell detection or cancer diagnosis. The present invention relates to a reagent for cancer cell detection, comprising a recombinant virus where a replication cassette comprising a promoter from human telomerase, an E1A gene, an IRES sequence and an E1B gene in this...

20060067891 - Metered dose spray device for use with macromolecular pharmaceutical agents such as insulin: A metered dose spray device administers medicine contained therein to the buccal cavity within a user's mouth upon actuation of the device. A metered dose spray device comprising an insulin solution is also provided....

20060067892 - Topical nanoparticulate spironolactone formulation: The invention relates to a topical nanoparticulate spironolactone formulation comprising nanoparticles having a mean diameter, measured by a photon correlation spectroscopy, in the range of from about 300 nm to about 900 nm. The nanoparticles are incorporated into a crystalline network system comprising a dispersion of solid crystals of polar...

20060067895 - Composite particle and process for producing the same: The invention provides a composite particle, a process for producing the same, and cosmetics containing the same The invention relates to composite particles containing a polyolefin-based resin having a crystallization degree of 80% or less and zinc oxide and obtained by hot melt microencapsulation or spray cooling, or composite particles...

20060067896 - Composition of sunscreen and color-changing markers: A sunscreen/sunblock product that combines sun protection and color marking activities intended to encourage use of sunscreen, especially among young children. The sunscreen/sunblock product also enables a user to visualize when the product needs to be re-applied. The sunscreen composition incorporates a color-triggering developer into commercially available sunscreens. This sunscreen...

20060067894 - Film foaming hydroalcoholic foam: The present invention provides a foam composition comprising an active agent. In particular, the foam composition produces a water resistant, preferably very water resistant, film upon application....

20060067897 - Process for the preparation of an extract with carotenoids, uv absorption, antibacterial and ph indicating properties from a deep-sea bacterium: Accordingly the present invention provides a process for the preparation an alcoholic extract with Carotenoids, UV absorption, antibacterial and pH indicating properties from a deep-sea bacterium which comprises a method for growing the cells in a medium with salinity ranging from 1.5 to 3% for 3-4 days at 28+/−2° C....

20060067893 - Uv-absorbing lipid vesicles: c

20060067898 - Antifungal nail coat and method of use: A dual action antifungal nail coat composition and method of use for ameliorating or preventing fungal infection of the nails, and onychomycosis, in particular, is disclosed. Composition embodiments in the form of one-coat type and two-coat type suitable for daily fungicidal regimens are disclosed. A preferred antifungal nail coat composition...

20060067899 - Paint for skin: A paint for skin which can eliminate the possibility that the paint will drip off or that there will blurring or mixing of colors with rain or sweat when the paint is used for a face paint or body paint, and which can be removed easily and completely only with...

20060067900 - Method and composition for imparting high shine to a polymeric substrate: A method and composition for imparting high shine to a polymeric substrate such as hair or skin, leather or a plastic which comprises applying thereto a phenylethyl or benzyl ester....

20060067901 - Antiperspirant compositions: What is described herein is an antiperspirant composition including an active antiperspirant ingredient, and a phenylethyl, benzyl or substituted benzyl ester as additive therein, which is an aryl carboxylic ester of 2-phenylethyl alcohol, 1-phenylethyl alcohol or benzyl alcohol, which leaves a reduced visible white chalky residue on the skin of...

20060067902 - Oil-in-water emulsion type cosmetic preparation: The present invention relates to an oil-in-water emulsion type cosmetic preparation that can offer excellent skin feel (non-sticky feel and long-lasting moisturizing feel) and exhibit excellent long-term emulsion stability, containing (A) one or more members selected from the group consisting of ester compounds which are reaction products of erythritol and/or...

20060067903 - Reduction of hair growth: Compositions including a conjugate of α-difluoromethylomithine can be applied topically to reduce hair growth....

20060067904 - Cosmetic compositions containing amphiphilic silicone resin emulsifier: An internally compatible cosmetic composition comprising at least two internally incompatible phases or ingredients that are compatibilized with an effective amount of an amphiphilic silicone resin emulsifier and a method for emulsifying an anhydrous or emulsion cosmetic composition containing at least two internally incompatible phases with an amphiphilic silicone resin...

20060067906 - Extended wear low viscosity cosmetic compositions: Extended wear compositions are disclosed which include the use of silicone resin, a dimethicone solvent, a low viscosity dimethicone dispersant having a viscosity of less than 1,000 cps and a high concentration of colorant or pigments. The resultant low viscosity compositions can be dispensed with a felt tip applicator and...

20060067905 - Formulations and method for treating baldness: The present invention includes 1) a novel formulation for the treatment of hair loss comprising oleanolic acid (a 5α-reductase inhibitor), apigenin (a vasodilator), and biotinyl-GHK (a cell metabolism stimulant), 2) a novel additive for the treatment of hair loss comprising oleanolic acid, apigenin, biotinyl-GHK and a delivery agent, 3) a...

20060067907 - Cationic or cationizable polyurethane with elastic character: A cationic or cationizable polyurethane with elastic character formed by the reaction of: (a1) at least one cationic or cationizable unit resulting from at least one tertiary or quaternary amine having at least two reactive functions with labile H, (a2) at least one mixture of at least two different non-ionic...

20060067908 - Methacrylate copolymers for medical devices: A polymer of hydrophobic monomers and hydrophilic monomers is provided. It is also provided a polymer blend that contains the polymer and another biocompatible polymer. The polymer or polymer blend and optionally a biobeneficial material and/or a bioactive agent can form a coating on an implantable device such as a...

20060067909 - Peptide-modified polyurethane compositions and associated methods: Peptide-modified polyurethanes comprising the reaction product of an isocyanate, a chain extender, and a peptide are provided. Also provided processes for making a peptide-modified polyurethane comprising: providing an isocyanate; providing a chain extender; providing a peptide; and allowing the isocyanate, chain extender, and peptide to react thereby forming the peptide-modified...

20060067910 - High-molecular weight derivatives of camptothecins: It is intended to provide water-soluble derivative of camptothecins which are excellent in therapeutic effect and suitable for chemotherapy for cancer. Namely, a water-soluble high-molecular weight derivative of camptothencins being excellent in sustained-release which is obtained by ester-bonding a carboxylic acid group of a polyethylene glycol-polycarboxylic acid polymer to a...

20060067911 - Metered medication dose: The invention discloses a metered medication dose of a dry powder protein medicament, particularly a peptide medicament, intended for inhalation by use of an adapted dry powder inhaler. An active peptide agent is presented in a pure, natural, crystalline, micronized, dry powder form. A dose comprises at least one such...

20060067912 - Methods for the induction of professional and cytokine-producing regulatory t cells: The field of the invention is generally related to methods used for the induction of T cells with suppressive activity. More specifically, the methods are used to generate professional regulatory T cells and cytokine-producing T cells with enhanced suppressive activity....

20060067913 - Hcv therapy: A peptide which has at least 80% identity to a fragment of Domain A or B of the Hepreceptor of ezrin, is used in the treatment of viral hepatitis....

20060067914 - Immortalized natural killer cell line: The present invention provides an immortalized natural killer cell line retaining the function and characteristics intrinsic to natural killer cells, a method for establishing the same, a method for screening for useful substances using the immortalized natural killer cell line, and a cell vaccine. By culturing natural killer cells obtained...

20060067920 - Chimeric immunoreceptor useful in treating human cancers: The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of...

20060067919 - Colon cancer metastasis inhibitor: The present invention provides an agent for inhibiting metastasis of colorectal cancer and a method for inhibiting metastasis of colorectal cancer, which inhibit the function of Asef (i.e., binding activity to the APC gene product or guanine nucleotide exchange factor activity) that binds to the gene product of the tumor...

20060067915 - Foaming composition of competitive exclusion microbes and method of using same: The present invention relates to a composition including a microbial component and a foaming component, wherein the composition can be used to prevent the proliferation, or otherwise competitively exclude the continued growth of, undesirable microbes. The present invention also includes a method of using this composition....

20060067922 - Low water activity nutritional product having beneficial microbial and high oil content: The present invention relates to a composition for the oral administration of beneficial microorganisms in a discrete dosage form, comprising about 10% to about 50% by weight of a starch component, about 25% to about 50% by weight of a sugar component, about 0-20% of a humectant component, and about...

20060067923 - Preventing agent against drug-resistant bacterial infection: By using lactic acid bacteria, their dead bacteria or treated substances thereof, or Mygasphaera elsdenii as active components, for an agent for preventing and treating drug-resistant bacterial infection for livestock/fowls or fish and shellfish carrying or being infected by drug-resistant bacteria such as Vancomycin, particularly by using Enterococcus faecalis, Enterococcus...

20060067924 - Probiotic bacteria and methods: Provided herein are molecular methods for assessing the state of gastrointestinal microflora of an animal, especially a species of poultry, and methods for identifying probiotic bacteria by comparing certain bacteria present in animals fed a diet not containing antibiotics but absent or present in significantly lower numbers in animals fed...

20060067921 - Probiotic bacterium: lactobacillus fermentum: Variant of the bacterium Lactobacillus fermentum and its use in treating gastrointestinal disorders, disorders of the mucosal surfaces or disturbances in the immune system or status of a subject....

20060067918 - Cell lines: The present invention relates to cells obtainable from cell lines having the ECACC Accession Nos 04091601, 04110301 and 04092302....

20060067917 - Insulin delivery system: Aspects of the disclosure generally relate to insulin delivery systems and compositions having a insulin secreting β cell line or insulin secreting recombinant non-β cells sequestered in a glucose-responsive material. The disclosed insulin delivery systems can be surgically implanted in a host and can provide a continuous source of insulin...

20060067916 - Sperm cell process system: A semen or sperm cell process system to maintain or enhance the biological, chemical, physical, physiological, or functional attributes of sperm cells within the context of various collecting, handling, storage, transportation, separation, or insemination procedures....

20060067925 - Method and composition for inhibiting reperfusion injury in the brain: The present invention relates to a method for inhibiting reperfusion injury in the brain. The method involve injecting via the carotid artery or jugular vein an antioxidant-loaded nanoparticle. A nanoparticle formulation containing an inert plasticizer is also provided for sustained release of an active agent....

20060067926 - Novel serine threonine kinase member, h2520-59: The present invention relates to a serine threonine kinase. The invention also relates to nucleic acids encoding the kinase, vectors, host cells, antibodies and recombinant methods for producing the h2520-59 polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for h2520-59 and related products....

20060067928 - Heparinase iii and methods of specifically cleaving therewith: The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis , etc. have been discovered according to the...

20060067927 - Methods and compositions related to the modulation of intercellular junctions: The invention relates to compositions and methods for the modulation of the permeability of the epithelial cell barrier complex. In particular, the invention provides compositions and methods for using polysaccharides, preferably glycosaminoglycans, and agents that modify cell surface glycosaminoglycans, preferably glycosaminoglycan-degrading enzymes to modulate intercellular junctions. The compositions and methods...

20060067929 - Clostridial toxin derivatives and methods for treating pain: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting...

20060067930 - Polypeptide variants with altered effector function: The invention provides polypeptides having IgG Fc regions with amino acid modifications that result in the polypeptides exhibiting altered Fc effector functions....

20060067931 - Receptor for lysophosphatidylcholine in vascular endothelial cells and use thereof: A paratope-containing molecule that specifically binds to human GPR4 is disclosed. That molecule preferably specifically binds to an epitope present in the C-terminal 40 residues of human GPR4. Methods of using the paratope-containing molecules and a kit containing the same are also disclosed....

20060067932 - Antagonists specific for denatured collagen and methods of using same: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen but not to native triple helical forms of the collagen. Antagonists of the invention can target, for example, denatured collagens type-I, type-II, type-III, type-IV, type-V and combinations...

20060067934 - Glycoproteins which bind to tnf: Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed....

20060067933 - Soluble receptor br43x2 and methods of using: Soluble, secreted tumor necrosis factor receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise one cysteine-rich repeat that is homologous to other tumor necrosis factor receptors, such as transmembrane activator and CAML-interactor (TACI). The polypeptides may be used for detecting ligands, agonists and...

20060067935 - Compositions and methods for inhibiting drusen complement components c3a and c5a for the treatment of age-related macular degeneration: Activated C3 (C3a) and its receptor (C3aR) and activated C5 (C5a) and its receptor (C5aR) have been shown to induce vascular endothelial growth factor (VEGF) expression in vitro and in vivo. Compositions and methods for inhibiting C3a, C3aR, C5a and C5aR for the treatment and/or prevention of neovascular disease are...

20060067936 - Il-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses: An anti-IL-23 specific human Ig derived protein, isolated nucleic acids that encode at least one anti-IL-23 Ig derived protein, vectors, host cells, transgenic animals or plants, and methods of making and using thereof are useful as therapeutic and diagnostic compositions, methods and devices. The anti-IL-23 Ig derived protein preferably binds...

20060067937 - Methods of diagnosing and treating complications of pregnancy: Disclosed herein are methods for diagnosing a pregnancy related hypertensive disorder or a predisposition to a pregnancy related hypertensive disorder by measuring the level or biological activity of soluble endoglin. Also disclosed herein are methods for treating a a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds...

20060067938 - Methods for the treatment of osteoarthritis and compositions thereof: The invention discloses PI3K, PKB, IL-1, and OSM as suitable targets for the development of new therapeutics to treat, prevent or ameliorate osteoarthritis (OA). The invention relates to methods to treat, prevent or ameliorate OA and pharmaceutical compositions therefor comprising substances with inhibitory effects on PI3K and/or PKB enzyme activity...

20060067939 - Nanotubes for cancer therapy and diagnostics: The present invention provides a novel approach to cancer therapy and diagnostics that utilizes nanotubes and other similar nanostructures as both an indirect source of radiation therapy (BNCT), and as delivery vehicles for other types of radio- and chemo-therapeutic materials, as well as imaging agents for diagnostic purposes....

20060067940 - Antibodies against west nile virus and therapeutic and prophylactic uses thereof: The present invention relates to compositions comprising antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV), and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV), infection utilizing said compositions....

20060067941 - Nanotubes for cancer therapy and diagnostics: The present invention provides a novel approach to cancer therapy and diagnostics that utilizes nanotubes and other similar nanostructures as both an indirect source of radiation therapy (BNCT), and as delivery vehicles for other types of radio- and chemo-therapeutic materials, as well as imaging agents for diagnostic purposes....

20060067942 - Pharmaceutical agent comprising amino acids, peptides, proteins and/or fractions and fragments thereof and the use of same in the prophylaxis and treatment of immune system deficiency in humans and animals: The invention relates to a composition of proteins, peptides and/or peptide components, to a pharmaceutical agent comprising said composition, to a method for the production of said composition, and to the use thereof in the prophylaxis or therapy of persons, animals and/or patients with pathogenic modifications and/or cellular immunodeficiencies, especially...

20060067943 - Stabilization of alum-adjuvanted immunologically active agents: A composition and method for formulating and delivering an adjuvanted immunological active agent, especially a vaccine, wherein adjuvant coagulation and concomitant loss of vaccine efficacy enhancement is mitigated or avoided. The adjuvanted, immunologically-active agent can be subjected to freezing, drying, freeze-drying, or lyophilization, and when reconstituted, retains a high level...

20060067944 - Stable immunogenic product comprising antigenic heterocomplexes: The invention relates to a stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject. The invention is characterised in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in...

20060067945 - Production of recombinant protein pap 31 for the diagnosis and prevention of bartonella bacilliformis infection: The invention relates to a recombinant DNA and polypeptide sequence of an immuno-dominant phage particle associated protein from Bartonella bacilliformis. The recombinant protein is easily produced permitting the conduct of more accurate and rapid diagnositic assays for the detection of B. bacilliformis infection with reduced reagent and equipment requirements over...

20060067946 - Method of treatment using ligand-immunogen conjugates: A method and pharmaceutical composition are provided for enhancing the endogenous immune response-mediated elimination of a population of pathogenic cells in a host animal wherein the pathogenic cells preferentially express, uniquely express, or overexpress a binding site for a particular ligand. The invention comprises administering the ligand conjugated to an...

20060067947 - Immunotherapeutic for cancer: There is provided means for increasing complete remission rates and shortening a period to complete remission and for achieving a synergistic effect with immunotherapy that is directed at bringing about enhanced effects from molecule-targeting therapeutic drugs. More specifically, an object is to achieve a synergistic effect by combining use of...

20060067948 - Viral vectors: A Human Immunodeficiency Virus (HIV-2) vector having a mutation within a packaging signal such that viral RNA is not packaged within an HIV-2 capsid is described. A further vector comprises an HIV-2 packaging signal and a heterologous gene capable of being expressed in the vector. These vectors may be co-transfected...

20060067949 - Immunization with porphyromonas gingivalis protects against heart disease: The invention is directed to a method of preventing and treating a patient having a risk factor and/or a symptom of cardiovascular disease using an immunogenic composition comprising an immunogenically effective portion of Porphyromonas gingivalis in a pharmaceutically effective carrier substance, and a vaccine for same....

20060067950 - Clostridial neurotoxins for use in wound healing: Naturally occurring and/or modified Clostridium neurotoxins, including those neurotoxins free of complexing proteins which naturally form complexes with Clostridial neurotoxins, are used to enhance healing of injured surface or superficial tissue of a patient by local administration into or in close proximity to the injured tissue. Such neurotoxins may be...

20060067951 - Signal peptides, nucleic acid molecules and methods for treatment of caries: Peptide analogues of S. mutans CSP peptide which inhibit biofilm formation, uses thereof in the preparation of pharmaceutical compositions, antimicrobial compositions and uses thereof in the treatment and prevention of infections caused by biofilm forming bacteria, dental plaque formation, and conditions caused by dental plaque associated bacteria are provided....

20060067955 - Biocompatible polymeric systems carrying triflusal or htb: New biocompatible polymeric systems carrying triflusal or HTB are described which result from the polymerization of a monomer A of the acrylic or vinylic type and carrying triflusal or HTB, wherein triflusal or HTB are linked to the remainder of the molecule of said monomer through an in vivo hydrolysable...

20060067954 - Lipid stabilized formulations: The present invention provides a lipid based system for isolating components in a pharmaceutical formulation. Also provided are methods for preparing stable pharmaceutical formulations containing at least two active ingredients. Further provided are methods of treating helminthiasis in mammals, which comprises administering a pharmaceutical composition that is highly effective against...

20060067952 - Low oil emulsion compositions for delivering taxoids and other insoluble drugs: The present invention provides injectable oil-in-water emulsions of taxoid drugs or other water insoluble drugs. The present invention also provides methods for preparing and using such oil-in-water emulsions....

20060067953 - Oral pharmaceutical formulations and methods for producing and using same: Oral pharmaceutical formulations and methods of producing and using the same are described and claimed. The formulations are dispersions of phospholipids and one or more pharmacologically active compounds, In preferred embodiments, the pharmaceutically active compounds are ansamycins, pharmaceutically acceptable salts, or prodrugs thereof....

20060067960 - Color cosmetic compositions: Cosmetic compositions containing at least one homopolymer or random copolymer obtained from the polymerization of nonpolar hydrocarbon diene monomers....

20060067959 - Compositions and methods for treatment of solar damage: An improved composition for treatment of the skin comprises: (1) methionine and cysteine in a quantity sufficient to accelerate restoration of the integrity and fullness of the skin; (2) a mixture of essential amino acids in a quantity sufficient to accelerate restoration of the integrity and fullness of the skin,...

20060067963 - Gel compositions and methods of producing same: Gel compositions and methods of synthesis thereof. The present invention discloses and describes a stable polymeric gel that exhibits highly desirable characteristics, including long term stability over a large temperature range while at the same time including volatile organic compounds into the gel. The gels of the present invention preferably...

20060067956 - Interface stabilisation of a product with 2 or more phases with a protein-polysaccharide complex: The present invention concerns a product taken from the group consisting of a foam, an emulsion, a foamed emulsion, a dispersed emulsion and a foamed dispersion, wherein the interface water-air, water-oil or water-solid comprises a complex formed instantaneously by the mixture of at least a protein (or peptide) and at...

20060067958 - Pharmaceutical topical gel compositions: Topical alcoholic gel compositions containing dissolved pharmaceutical actives, which, in their preferred form, have excellent clarity. The alcoholic gel contains less than 20% w/w water, and uses hydroxypropylcellulose and non-neutralized, partially neutralized, or fully neutralized acrylic acid-based polymer as effective synergistic gelling system, and diols and/or triols as an optional...

20060067957 - Self-heating cosmetic products: The invention refers to cosmetic products having a self-warming effect. The composition is substantially water-free and contains 0.1 to 40% by weight of a hydrophilic aluminum-rich zeolite with a pore size in the range of 0.3 to 0.5 nm, 1 to 99% by weight of a disperse oil phase, 0.1...

20060067961 - Skin cooling compositions: In some embodiments, the present invention relates to skin cooling compositions and methods for preparing skin cooling compositions. The skin cooling compositions provide immediate cooling of the skin as well as longer term cooling of the skin. In some embodiments, the cooling composition includes water, alcohol, a surfactant and a...

20060067962 - Skin cooling compositions: The present invention relates to an applicator and method for cooling skin. The applicator includes a substrate and a skin cooling composition that is attached to the substrate. In some embodiments, the skin cooling composition includes water, alcohol, a surfactant and a water dispersible silicone. As used herein, a water...

20060067964 - Decal that includes synergistic antimicrobials for treating surfaces: The present invention relates to a decal and method for treating a surface. The decal includes a web and an agent for treating the surface. The decal further includes a bonding material that attaches the decal to the surface. In some embodiments, the agent may be attached to the web...

20060067965 - Fiber for eliminating human-based odors and repelling insects: A fiber having insect repellant capabilities. The fiber includes an insect repellant and another material capable of eliminating odor, such as human body odor. In one embodiment, the material capable of eliminating odor is silver. Other materials may include, carbon, copper, a ceramic, or a combination thereof. The insect repellant...

20060067968 - Bioactive agent release coating: A coating composition for use in coating implantable medical devices to improve their ability to release bioactive agents in vivo. The coating composition is particularly adapted for use with devices that undergo significant flexion and/or expansion in the course of their delivery and/or use, such as stents and catheters. The...

20060067966 - Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents: Combinations of hydrophilic and hydrophobic entities in a biodegradable sustained release implant are shown to modulate each other's rate of release. Formulations of a therapeutically active agent and modulator provide substantially constant rate of release for an extended period of time....

20060067967 - Reinforced foam implants with enhanced integrity for soft tissue repair and regeneration: A biocompatible tissue repair stimulating implant or “scaffold” device is used to repair tissue injuries, particularly injuries to ligaments, tendons, and nerves. Such implants are especially useful in methods that involve surgical procedures to repair injuries to ligament, tendon, and nerve tissue in the hand and foot. The repair procedures...

20060067970 - Method for producing decalcified hard tissue sample: A method for producing a decalcified hard tissue sample by embedding a hard tissue in a liquid-penetration-permitting resin, and then decalcifying it....

20060067969 - Multi-phased, biodegradable and osteointegrative composite scaffold for biological fixation of musculoskeletal soft tissue to bone: Methods and apparatuses are provided for musculoskeletal tissue engineering. For example, a scaffold apparatus is provided which comprises microspheres of selected sizes and/or composition. The microspheres are layered to have a gradient of microsphere sizes and/or compositions. The scaffold provides a functional interface between multiple tissue types....

20060067971 - Bone void filler: Novel biodegradable bone void filler compositions. The bone void filler compositions have a biodegradable material component, an osteoconductive component, and a therapeutic agent. The bone void filler optionally contains an osteoinductive component. Also disclosed is a method of using the bone void filler compositions to fill a bone void....

20060067973 - Bone void filler: Novel biodegradable bone void filler compositions. The bone void filler compositions have a biodegradable material component, a porous osteoconductive component, and a therapeutic agent. The bone void filler optionally contains an osteoinductive component. Also disclosed is a method of using the bone void filler compositions to fill a bone void....

20060067972 - Devices for renal-based heart failure treatment: Methods and devices are provided to preferentially deliver biologically active substances to a patient's renal artery, particularly for the treatment of congestive heart failure. The apparatus will comprise an implantable depot which may be in the form of a biodegradable vascular implant, a replenishable reservoir, a drug pump, or combinations...

20060067974 - Drug delivery coating for use with a stent: A coated medical device an a method of providing a coating on an implantable medical device result in a medical device having a bio-absorbable coating. The coating includes a bio-absorbable carrier component. In addition to the bio-absorbable carrier component, a therapeutic agent component can also be provided. The coated medical...

20060067976 - Formation of barrier layer: A barrier layer and corresponding method of making provide anti-inflammatory and anti-adhesion functionality for a medical device implantable in a patient. The barrier layer can be combined with a medical device structure to provide anti-adhesion characteristics, in addition to improved healing and anti-inflammatory response. The barrier layer is generally formed...

20060067977 - Pre-dried drug delivery coating for use with a stent: A method and apparatus for the provision of a coating for application to a medical device results in a medical device having a bio-absorbable coating. The coating includes a bio-absorbable carrier component. In addition to the bio-absorbable carrier component, a therapeutic agent component and solvent can also be provided. The...

20060067975 - Uv cured gel and method of making: A method of UV curing and corresponding resulting non-polymeric cross-linked gel are provided. The cross-linked gel can be combined with a medical device structure. The cross-linked gel can provide anti-adhesion characteristics, in addition to improved healing and anti-inflammatory response. The cross-linked gel is generally formed of a naturally occurring oil,...

20060067980 - Capsule for encasing tablets for surgical insertion into the human body: A drug delivery device for placement in a body includes a drug core comprising a pharmaceutically active agent, and a holder that holds the drug core. The holder is made of a material impermeable to passage of the active agent and includes at least one opening for passage of the...

20060067979 - Ophthalmic drug release device for multiple drug release: A drug delivery device for placement in the eye includes a drug core comprising a pharmaceutically active agent, and a holder that holds the drug core. The holder is made of a material impermeable to passage of the active agent and includes an opening for passage of the pharmaceutically agent...

20060067978 - Process for preparing poly(vinyl alcohol) drug delivery devices: The present invention is a process for making a plurality of drug delivery devices for implantation in the eye of a patient. The plurality of drug delivery devices are made in part of poly(vinyl alcohol). During the manufacturing process the poly(vinyl alcohol) is cured. The poly(vinyl alcohol) may be in...

20060067981 - Contact lens with improved biocidal activity and related methods and materials: The present invention is directed to a contact lens comprising a porous lens material and a disinfectant, including but not limited to domiphen bromide. The disinfectant is typically absorbed into the pores of the lens. The present invention also includes a related process for manufacture, method of use and kit....

20060067982 - Otorhinological delivery device: The invention relates to an otorhinological delivery device comprising at least one pharmaceutically active agent. According to the invention the device comprises a core comprising said at least one pharmaceutically active agent wherein said core is made of an elastomer composition selected from the group consisting of poly(dimethylsiloxane), a siloxane-based...

20060067983 - Stand-alone film and methods for making the same: A stand-alone film is derived at least in part from fatty acids. The stand-alone film can have anti-adhesive, anti-inflammatory, non-inflammatory, and wound healing properties, and can additionally include one or more therapeutic agents incorporated therein. Corresponding methods of making the stand-alone film include molding, casting, or otherwise applying a liquid...

20060067984 - Composition in micro-pellets with controlled release of physiologically active substances, procedure for their preparation and use in the zootechnical sector: The subject of this invention is a controlled release composition for zootechnical use. In particular, the subject of this invention is a composition comprising micro-pellets that are able to release the physiologically active substances they contain in a controlled manner. In addition, this invention refers to a procedure for preparing...

20060067987 - Composition, a food, and a beverage having an anti-obesity action: Compositions, foods, and beverages which contain a salt-free or a reduced-salt fermented soybean paste-like food material in which the salt content is 5% or less, obtained by hydrolyzing soybean by a koji mold have an excellent anti-obesity action....

20060067986 - Compositions and methods for treatment of body weight conditions: A nutritional supplement composition having therapeutically effective amounts of milk minerals including calcium, a protein source including kappa-casein fragment 106-169, and enzyme-inhibiting peptides is provided for the treatment of body weight conditions. The nutritional supplement composition is administered in amounts effective for limiting weight gain and/or enhancing weight loss, as...

20060067985 - Hypoallergenic composition: This invention is directed generally to compositions (including foods, supplements, treats, toys, etc.) for animal (including pet) consumption, and particularly hypoallergenic compositions, and more particularly semi-solid hypoallergenic compositions and hypoallergenic compositions that comprise a hydrolysate. This invention also is directed generally to methods for using such compositions. This invention is...

20060067988 - Pharmaceutical formulations designed to supplement the diet of anorexic patients: The present invention relates formulations designed to supplement the diet of patients who are anorexic, otherwise debilitated or convalescent, or suffer from other eating disorders, comprising casein hydrolysates and proteins derived from whey in the ratio of 1:1 and 1:5 in weight respectively....

20060067989 - Degradable animal chewing article possessing enhanced safety, durability, and mouth-feel: A chewable, biodegradable article for use as a pet toy comprises a matrix made of a natural polymer, a synthetic organic polymer or a mixture thereof, a natural or synthetic fibrous material that comprises fibers and that is bonded chemically or physically with the matrix material, and, optionally, includes one...

20060067990 - Absorbent articles for inhibiting the production of exoproteins: R7 is —OCH2—; X is 0 or 1; R5 is a substituted or unsubstituted aromatic ring or a monovalent saturated or unsaturated, substituted or unsubstituted, branched or straight chain hydrocarbyl moiety that may or may not be substituted with hetero atoms; R6 is selected from the group consisting of an...

20060067991 - Non-absorbent articles for inhibiting the production of exoproteins: R7 is —OCH2—; X is 0 or 1; R5 is a substituted or unsubstituted aromatic ring or a monovalent saturated or unsaturated, substituted or unsubstituted, branched or straight chain hydrocarbyl moiety that may or may not be substituted with hetero atoms; R6 is selected from the group consisting of an...

20060067992 - Wound dressing: A wound dressing comprises in combination (i) a first wound contact layer which preferably has a positive effect on the healing of the wound, and (ii) a second layer of greater hydrophilicity than the first layer....

20060067996 - Preventing/treating signs of skin stress/aging by bioenergetically modifying acupuncture points of the face or neck: A regime or regimen for preventing and/or treating the signs of aging and/or stress of the skin, especially for (i) smoothing skin wrinkles and/or relaxing marks on the forehead and/or (ii) tonifying the cheeks, entails topically applying, advantageously via transdermal delivery, onto at least one acupuncture point of the face...

20060067994 - System for providing therapy to a body: Some embodiments of the present invention relate to a system, kit and method for providing therapy to a portion of a body. The system includes a holder and a therapeutic patch that is held by the holder. The therapeutic patch applies therapy to the portion of the body when the...

20060067995 - Topical and/or transdermal bioactive compound delivery system: Topical and/or transdermal bioactive compound delivery system The present invention provides a topical and/or transdermal bioactive compound delivery system comprising a non-aqueous matrix, the matrix comprising a water-sensitive bioactive compound. In particular, the matrix comprises a three-dimensional polymeric network comprising at least a co-polymer, at least a cross-linking agent, and...

20060067993 - Topical anesthetic patch: A pre-vaccination or pre-procedural topical anesthetic patch which functions not unlike a nicotine patch and which is essentially a round Band-Aid® containing a topical anesthetic. The Band-Aid® anesthetic carrying device may be of any shape or size. It is applied to a persons skin at a site where a needle...

20060067998 - Liposomal curcumin for treatment of cancer: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery...

20060067997 - Phospholipid complexes of lexitropsins, their preparation and use in therapeutic formulations: Pharmaceutical formulations constituted by a lexitropsin phospholipidic complex in the form of liposomes, micelles or nanoparticles exhibit optimal pharmacological properties in respect to other formulations containing active principles belonging to the same chemical class in both the topical or parenteral treatment of infectious and/or tumour diseases....

20060067999 - Extended release formulation: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of...

20060068000 - Extended release formulation: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of...

20060068001 - Extended release formulation: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of...

20060068002 - Extended release formulation: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of...

20060068004 - Buccal delivery of sea cucumber tablets: This invention is directed to a composition and method for the buccal delivery of sea cucumber extract. The composition for the buccal delivery of sea cucumber extract comprises a substantially uniform mixture of an effective amount of sea cucumber extract and sugar. In one embodiment of the invention, the sea...

20060068005 - Chewable electrolyte tablet: A chewable electrolyte tablet. The chewable electrolyte tablet includes an agent to prevent stomach irritation, a flavoring agent, a sweetening agent, or a combination thereof to enable the tablet to be palatable and, therefore, ingested through simple mastication and without the need for water, thereby permitting the amount of water...

20060068007 - Class of surfactant-like materials: This invention generally refers to a novel class of surfactant-like material that promotes the solubility of poorly soluble compounds....

20060068006 - Edible holographic products, particularly pharmaceuticals and methods and apparatus for producing same: An edible product such as a unit dosage form of a pharmaceutically active substance includes a layer of a material that can receive and retain a high resolution microrelief that can convey information. The microrelief is themo-formable, preferably formed from an aqueous solution of HPMC and/or HPC plus a plasticizer...

20060068008 - Lyophilized pharmaceutical compositions: Pharmaceutical compositions that include a poorly water-soluble therapeutic compound, an aqueous solvent, a nonvolatile cosolvent and a bulking agent. The pharmaceutical compositions can be orally ingested or administered parenterally. The pharmaceutical compositions can further be lyophilized to form a pharmaceutically acceptable cake that can be administered orally, e.g., as a...

20060068003 - System for increasing compliance with medication regime: A drug-dispensing arrangement for dissociating side effects, particularly gastrointestinal side effects, such as nausea and/or vomiting, from oral ingestion of a medication eliminates the development of learned taste-aversion. If a large, random and unpredictable order of flavors, and preferably well-known and pleasant flavors, are experienced by a patient in conjunction...

20060068009 - Modified release ibuprofen dosage form: The present invention is a solid dosage form for oral administration of ibuprofen comprising a modified release formulation of ibuprofen which provides an immediate burst effect and thereafter a sustained release of sufficient ibuprofen to maintain blood levels at least 6.4 μg/ml over an extended period of at least 8...

20060068010 - Method for improving the bioavailability of orally delivered therapeutics: The disclosed invention is a method and composition for improving the bioavailability of a pharmaceutically active ingredient comprising an oral dosage form consisting essentially of a granulation of active ingredient, amino acid, and hydrophilic polymer, wherein the granulation is dispersed in an immediate release or extended release excipient....

20060068011 - Simultaneous encapsulation technique for use in pharmaceutical compositions: Multiple active pharmaceutical ingredients may be simultaneously encapsulated into pellets using the melt pelletization technique. The resulting pellets exhibit high active ingredient content and good handling characteristics, such as flowability, lubrication, compression, and size distribution, for production of a solid dosage form of a pharmaceutical composition. A method for preparing...

20060068012 - Process for preparing poly (vinyl alcohol) drug delivery devices with humidity control: The present invention is a process for making a plurality of drug delivery devices for ocular delivery. The plurality of drug delivery devices are made in part of poly(vinyl alcohol). During the manufacturing process the poly(vinyl alcohol) is cured. The poly(vinyl alcohol) may be in the form of separate pieces,...

20060068013 - Non-adhesive elastic gelatin matrices: The present invention is a substantially non-adhesive elastic gelatin matrix. The matrix is both non-adhesive to wounds, tissues and organs and is also elastic such that it is flexible. The matrix is a lyophilized mixture of protein(s), polymer(s), cross-linking agent(s) and optional plasticizer(s). The invention also provides methods for making...

20060068014 - Ionic hydrogels with controlled aqueous fluid absorption: A cross-linked plasticised polymeric hydrogel suitable for use in mammalian body tissue (e.g. skin) contacting applications, which comprises a cross-linked copolymer formed from a first monomer comprising one or more pendant anionic group and a second monomer comprising one or more pendant cationic group, the relative amounts of the said...

20060068017 - Extended release formulation: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of...

20060068018 - Extended release formulation: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of...

20060068016 - Paticulate product comprising pantethine: A particulate containing a pantethine, a light anhydrous silicic acid and a microcrystalline cellulose, in which the total content of the light anhydrous silicic acid the microcrystalline cellulose amounts to a quantity that yields a 0.6 or higher adsorptivity. The present pantethine-containing particulate has a good flowability and an adequate...

20060068015 - Solid dosage form comprising a fibrate and a statin: The present invention relates to pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of a fibrate, notably fenofibrate, and a statin (also known as a HMG CoA reductase inhibitors), which compositions are manufactured without any need of addition of water or an aqueous medium and...

20060068019 - Coated polyunsaturated fatty acid-containing particles and coated liquid pharmaceutical-containing particles: A process for coating a polyunsaturated fatty acid (PUFA)-containing carrier particle or a PUFA matrix particle, or a liquid pharmaceutical-containing carrier particle or a liquid pharmaceutical matrix particle. Also disclosed are such particles made by the process of the invention and foods, pharmaceuticals, beverages, nutritional supplements, infant formula, pet food...

20060068020 - Encapsulated pharmaceutical agents: The present invention provides stable lipid-based pharmaceutical formulations containing ivermectin, praziquantel and pyrantel pamoate, and methods for preparing the formulations. Further provided is a method of treating helminthiasis of mammals, which comprises administering a pharmaceutical composition that is highly effective against helminths, particularly tapeworm, hookworm, roundworm and heartworm of domestic...

20060068021 - Sustained-release microencapsulated delivery system: Disclosed is a process for producing sustained-release powders that is fast, efficient, and economical. The process involves melting a naturally derived oil with a melting point above 110° F. in specially designed mixer through either the work energy input of the mixer shaft itself, or a specially fitted plow type...

20060068022 - Bioactive agent compositions for repair of cell injuries: A method for prophylactically treating a gastrointestinal disorder or skin ailment in a mammal through the administration of an enhanced bioactive agent composition comprising a bioactive agent and at least one of a soy product, licorice product, or sodium bicarbonate (depending upon the indication to be treated) is provided according...

20060068023 - Chewable tablet containing lysine: A tablet with enhanced compliance by humans, in particular children and/or juveniles, comprising: (a) a vitamin; (b) lysine or a pharmaceutically acceptable salt thereof; (c) a sweetener; and (d) a pharmaceutically or dietetically acceptable carrier....

20060068024 - Antimicrobial silver halide composition: This invention relates to a composition comprising at least 50% water, silver halide particles and a hydrophilic polymer, wherein the composition does not substantially gel or solidify at 25 degrees C.; is substantially free of organic solvents; and exhibits antimicrobial activity upon drying. The composition may further comprise a hydrophobic...

20060068025 - Silver microribbon composition and method of making: This invention relates to a composition of matter comprising predominantly silver metal microribbons, wherein the microribbons are at least 1 micron in length×0.1 to 0.5 microns in width×0.05 to 0.5 microns in height. It further relates to a method of making predominantly silver microribbons comprising providing a reducible silver salt,...

20060068026 - Thermal electrochemical synthesis method for production of stable colloids of \"naked\" metal nanocrystals: A method of making a colloidally stable suspension of naked metal nanocrystals includes the steps of: at least partly immersing a metallic sacrificial anode and a cathode into a body of essentially contaminant-free water, the metallic sacrificial anode that includes an essentially contaminant-free metal starting material for making nanocrystals; and...

20060068027 - Methods for regulating levels of zinc, cadmium and calcium in humans and for diagnosing, or screening for the risk of developing, diseases associated with abnormal levels of cadmium, zinc and calcium in body fluids and tissues: Methods and compositions are provided for decreasing PGE2:PGF2α, regulating ratios of zinc:cadmium and regulating the concentration of zinc, calcium and zinc-containing and PGE2-dependent matrix metalloproteinases in body fluids and tissues of a human. Elevated or otherwise unregulated levels of PGE2, zinc and calcium and elevated concentrations of zinc-containing and PGE2-dependent...

20060068028 - Means of prevention for hiv/aids infections, grippe and flu: For the prevention of HIV/AIDS and venereal diseases, grippe and flu, it is proposed to use the offered solutions and other creams possessing virucide and bactericidal characteristics for processing the possible infected area of the skin and mucous membranes of the body, and also solutions for inhalation for the grippe...

20060068029 - Method of treating with chlorine dioxide: An aqueous chlorine dioxide solution which comprises dissolved chlorine dioxide in a concentration of about 10 to 3000 mg/l, pH in the range of about 1 to 6, and a chlorine scavenging means such as sodium chlorite in a ratio in the range of about 1:4 to 1:15 (w/w) sodium...

20060068030 - Individual need-based system for providing supplements: A system for individual need-based determinations relative to the use of a substance is presented in various embodiments. As applied to supplements the system may be configured to present a test modality (6) which may be attached to a distribution container (1) within which supplements (2) or the like may...

20060068031 - Use of exogenous gasoues nitric oxide in the treatment and disinfection of biofilms: The administration of gaseous nitric oxide as a biocidal moiety is proffered as a de novo treatment in the control and eradication of biofilms. The present invention relates to the use or methods of application of exogenous nitric oxide gas (gNO) as a stand alone biocidal agent or in cohort...

20060068033 - Alternative remedy-based composition for enhancing fertility: A plurality of herbs is combined to produce a composition that enhances and promotes fertility in females. One herbal composition comprises 40 herbs, the so-called “A” formula, and another herbal composition comprises 40 herbs, the so-called “B” formula. Some herbs are present in both formulas. The second formula is administered...

20060068032 - Compositions and methods for treating angiogenesis-related diseases, wounds and cosmetic use of components of angelica sinensis, and methods of preparation thereof: Compositions and methods for treating angiogenesis-related diseases and for skin care in mammals is disclosed that includes, as an active pharmaceutical agent, an effective amount of purified extract from Angelica sinensis, or a fraction or a lyophilizate thereof, or one or more active component contained in said extract....

20060068036 - Extract of dioscorea sp. and the medical uses thereof: The present invention provides a method for treating osteoporosis in a subject in need of such treatment, including administering orally to the subject an effective amount of an extract product of a Dioscorea species capable of promoting proliferation and differentiation of bone marrow cells in the subject, wherein the Dioscorea...

20060068035 - Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals: A method for isolating the bioactive component of the water-soluble extract of Uncaria tomentosa known as C-MED-100®, comprising (i) precipitating the spray drying carrier from C-MED-100®; (ii) using the resulting C-MED-100® to obtain a spotting mixture for thin layer chromatography (TLC); (iii) spotting the C-MED-100® spotting mixture on pre-run TLC...

20060068034 - Pharmaceutical formulation: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein...

20060068037 - Admixing process for making compositions containing vitamin e and saw palmetto: Processing conditions for preparing compositions that comprise Vitamin E and optionally saw palmetto. The compositions are preferably formulated with a zinc compound and a selenium compound....

20060068038 - Mineral additives for improved processing of compositions containing vitamin e and saw palmetto: Mineral additives for preparing tablet compositions that comprise Vitamin E and optionally saw palmetto. The compositions are preferably formulated with a zinc compound and a selenium compound....

20060068039 - Composition for the treatment of gastrointestinal disorders: The invention relates to a preparation comprising 5-50% by weight of Isphagula Husk; 1-20% by weight of at least one amino acid; 20-80% by weight of at least one carbohydrate and electrolytes. The preparation is for use as a therapeutical agent, such as for use in treating a state of...

20060068040 - Carrier-free composition for the treatment of onychomycosis: A composition for the treatment of onychomycosis (fungal nail disease) is described. The composition consists essentially of thymol, camphor, menthol and Eucalyptus citridiora as a colorless liquid oil without any carrier or solvent for these ingredients....

20060068042 - Method for producing composition containing soluble isoflavones: A method for producing a composition containing soluble isoflavones is described, which uses soybean materials as raw materials. The composition is obtained in a natural state without addition of solubilizing agents and chemical modification, and has high solubility under neutral to acidic conditions and good long-term stability under refrigeration. By...

20060068041 - Process for releasing and extracting phosphatides from a phosphatide-containing matrix: A process for releasing and extracting phosphatides from a phosphatide-containing matrix. The process includes (i) contacting the phosphatide-containing matrix with a solvent and a metal salt to release phosphatides from the matrix and form a phosphatide enriched solvent portion and a phosphatide depleted matrix portion, (ii) separating the phosphatide enriched...

20060068043 - Composition for treating chronic venous insufficiencies using an extract of red vine leaves: The invention relates to a dietary supplement consisting of an aqueous extract of red vine leaves and an acceptable carrier which prevents and reduces the discomfort relating to mild-to-moderate chronic venous insufficiency of the legs....

20060068044 - Antimicrobial compositions and applications therefore: The present invention relates to a composition derived from an essential oil obtained from one or more plants of the Melaleuca family in which at least 80% of the monoterpene content of the oil has been removed. The present invention also relates to a number of applications of the composition...

20060068045 - Method for the preparation of phytoprogestogenic extracts from rhizoma ligusticum chuanxiong and uses thereof: A method of extracting phytoprogestogenic compounds from herbs and their use in preparing a medicament for treating humans requiring progesterone replacement or supplement. Assay systems to quantify progesterone and progestogenic receptor activity and a method for assembling a kit for the assays are also provided....

20060068046 - Zinc (ii)-rich natural materials using plant: To relieve symptoms caused by mineral deficiency such as taste abnormality and skin damage due to zinc deficiency, anemia due to iron deficiency and decreased bone mineral content due to calcium deficiency to thereby improve quality of life (QOL). Namely, foods such as foods for specific health uses and foods...

20060068047 - Adsorbent for endocrine disruptors and foods and drinks containing the same: An adsorbent for endocrine disruptors which contains as the active ingredient viable or dead cells of intestinal microorganisms or constituents thereof. When the adsorbent for endocrine disruptors and foods and drinks containing the same are orally taken either daily or simultaneously with endocrine disruptors typified by bisphenols, alkylphenols and triazines...

20060057062 - Compositions and methods useful in pretargeted imaging: Disclosed are multispecific macromolecular constructs, blocking agents and radiolabeled effector molecules, as well as kits and methods for imaging tissue of interest in a mammalian subject. The multispecific macromolecular construct is capable of binding a radiolabeled effector molecule that can be imaged, as well as a disease marker such as...

20060057064 - Compound binding to leukocytes and medicinal composition containing the compound in labeled state as the active ingredient: A compound binding to leukocytes, which comprises Met-Leu-Phe or Nle-Leu-Phe serving as the leukocyte-binding site of a formyl peptide receptor (FPR), a binding part comprising Ser or Thr elevating the binding ratios to monocytes and lymphocytes in all leukocytes, a group which can be labeled with a radioactive metal or...

20060057063 - Medicaments: A drug conjugate comprising a targeting agent and an anti-cancer agent, wherein said targeting agent comprises an erythropoietin receptor ligand, is described. The drug conjugate can be used in methods of treating cancer. Also described are methods of treating cancer using the conjugate, methods of diagnosis, methods of imaging and...

20060057068 - Ca ix-specific inhibitors: Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably organic compounds, preferably aromatic and heterocylic sulfonamides, which inhibit the enzymatic activity of MN/CA IX and that are useful for treating patients with preneoplastic/neoplastic disease....

20060057065 - Composition and method to prevent and treat brain and spinal cord injuries: The cerebrospinal fluid (CSF) contains low concentration of albumin and insulin because of the blood-CSF barrier. This is the major reason for cerebral edema and the resultant blood perfusion deficit when brain or spinal cord is injured. A composition and method for treating brain and spinal cord are provided. The...

20060057067 - Lymph-like composition and method to prevent and treat central nervous system injuries: The existence of the cerebrospinal fluid and the intracranial pressure contribute the susceptibility of the CNS to injuries. A lymph-like composition and method for treating brain and spinal cord injuries are provided. The lymph-like composition comprises Polypeptides, Insulin, Mg+ and ATP in an artificial cerebrospinal fluid. The method includes: a)....

20060057066 - Reagent sets and gene signatures for renal tubule injury: The invention discloses reagent sets and gene signatures for predicting onset of renal tubule injury in a subject. The invention also provides a necessary set of 186 genes useful for generating signatures of varying size and performance capable of predicting onset of renal tubule injury. The invention also provides methods,...

20060057071 - Paramagnetic complexes with pendant crown compounds showing improved targeting-specificity as mri contrast agents: Potential magnetic resonance imaging (MRI) contrast agents that are functionalized with crown compounds have been synthesized, and show target-specificity to the kidney and liver, along with excellent water solubility, high MR intensity enhancement efficiency, long resident lifetime, low dosage requirement, low cytotoxicity and prolonged excretion rate....

20060057070 - Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use: A composition comprising an albumin-based colloid composition having at least one protected thiol region, method of making the same, and method for use, including treating hypovolemic conditions such as capillary leak syndrome and shock, are disclosed. The composition also is modified with an indicator reagent such as chromophores....

20060057069 - Detection of protein expression in vivo using fluorescent puromycin conjugates: Disclosed is a class of reagents for examining protein expression in vivo that does not require transfection, radiolabeling, or the prior choice of a candidate gene. Further, a series of puromycin conjugates was constructed bearing various labeling moieties. These conjugates were readily incorporated into expressed protein products in cell lysates...

20060057072 - Method for diagnosis and treatment of vascular disease: A method for diagnosing decreased vascular function is disclosed. The method includes assaying the number of endothelial progenitor cells. A method for detecting increased cardiovascular risk is also disclosed, as is a method for diagnosing atherosclerosis. In one example, the methods include assaying the number of endothelial progenitor cells. A...

20060057073 - Wet granulation process: The invention is in the field of pharmaceutical dosage forms, and more particularly in the field of pharmaceutical granules and processes for making granules. The invention provides a process for preparing pharmaceutical granules which contain an active ingredient in the form of a salt, said process comprising the steps of...

20060057074 - Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics: The present invention relates to novel pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics, processes for preparing them and their use in the treatment of respiratory diseases....

20060057075 - Pharmaceutical and cosmeceutical wash-off mousse shampoo compositions, processes for preparing the same and uses thereof: A pharmaceutical or cosmeceutical mousse shampoo composition formulated for application to hirsute areas, such as the human scalp, and containing an active pharmaceutical ingredient as well as a cleansing agent is disclosed. Methods of treatment using the same and processes of preparing the same are also disclosed....

20060057077 - Dental care product: A masticating strip useful in dental hygiene consisting of a cellular foam in which the surface cells incorporate longitudinal slits. The strips are sized to give a chewing volume of 1 to 4 cm3 preferably about 3 cm3. The strips are made from a foam of a thermoplastic material selected...

20060057078 - Oral care tablet: A water soluble, non-abrasive, effervescent, pharmaceutically acceptable, oral care tablet for use in the oral cavity. The tablet includes a carbon dioxide source, a acid source and a tablet forming material admixed to form a chewable tablet having less than 0.2% water. The carbonate to acid ratio ranges from about...

20060057076 - Oral humectants: The invention provides a mouth wetting agent and a mouth wetting agent for false teeth including a safe and easily usable polymer composition and capable of relieving symptoms of dry mouth by maintaining the wetting properties of an oral cavity and the stability of false teeth. The mouth wetting agent...

20060057079 - System and method for evolving efficient communications: An improved system, method, service method, and data structure that facilitates collaboration with, communication of, and access to information, particularly in an education environment is disclosed. The invention includes a database having one or more records. Each record defines a logical connection between one or more querents and one or...

20060057081 - Compositions and methods for treatment of skin discoloration: A cosmetically acceptable product for application to human skin is disclosed. The novel compositions are particularly suited for skin lightening and for diminishing the appearance of “dark circles” under the eyes. The compositions include any of several vasoconstrictors in a carrier with optionally added skin compatible ingredients....

20060057080 - Ultra-violet inhibition system: The invention described herein includes a chemical system consisting essentially of octyl methoxycinnamate, oxybenzone, Ethylhexyl Salicylate, and Avobenzone and optionally, water. The chemical system imparts resistance to ultraviolet energy when added to cosmetic formulations, chemical formulations, and medicinal formulations....

20060057083 - Cosmetic composition comprising at least one diamantoid to improve the mechanical properties of some materials: The present disclosure relates to a cosmetic composition comprising, in a cosmetically acceptable medium, at least one diamantoid comprising at least two adamantane units. The present disclosure further relates to a method for treating keratin materials, as well as a method for improving the mechanical properties of some materials that...

20060057082 - Topical aqueous composition as nail hardener to decrease brittleness and increase strength: The present invention is based upon the surprising discovery that the offering aqueous composition according to the invention is capable of being used as topical nail hardener. The present invention relates to a nail hardener that employs a composition of glycerin and water in the preferred concentration as the active...

20060057085 - Anhydrous care or make-up composition containing fibers and polyols: An anhydrous care or make-up composition for keratin substances such as the skin, the lips or superficial body growths, containing fibers which are compatibilized with a fatty phase by at least one polyol that is liquid at room temperature, wherein this composition is, in particular, a foundation or a lipstick...

20060057084 - Attero-chromic color aggregates: Compositions are provided which change color or modify a color characteristic of a personal care product in response to the application of mechanical energy, such as is provided by the user during application of the product. Methods of making color-changing compositions and personal care products incorporating color-changing compounds are also...

20060057086 - Long wearing composition for making up eyes, skin, and lips: A composition for making up the eyes and skin comprised of a liquid carrier containing at least one film forming polymer, and dispersed therein at least one organic pigment forming the main color component of the composition as well as a method for improving the wear of cosmetic compositions for...

20060057087 - Oral care implement: An oral care implement is provided having a handle and a head with a soft tissue cleanser and/or tooth cleaning elements. The tooth cleaning elements may be flexibly mounted in the head for movement from an initial position with respect to the head during use. The soft tissue cleanser may...

20060057088 - Vaccine for hair removal: A process for delivering hair removal fluids to hair ducts. In a preferred embodiment the fluid is a vaccine for slowing or stopping hair growth and a process for applying the vaccine or other hair growth vaccines to the skin region having unwanted hair and a method of delivering the...

20060057089 - Highly concentrated oil-in-water silicone emulsions: Highly concentrated oil-in-water aqueous emulsions of nitrogen-containing organopolysiloxanes are prepared by dispersing the organopolysiloxanes in water without substantial addition of acid, to form a flowable, dilutable, storage stable emulsion containing 45 weight percent or more organopolysiloxane and a pH of at least 7.5....

20060057096 - Cosmetic composition comprising at least one cationic surfactant, at least one aminated silicone, at least one fatty alcohol, and at least one diol: Disclosed herein is a cosmetic composition, in particular a hair composition, comprising, in a cosmetically acceptable medium, at least one quaternary ammonium cationic surfactant, at least one aminated silicone, at least one fatty alcohol, and at least one diol comprising 6 carbon atoms....

20060057097 - Conditioning shampoo composition: Aqueous hair cleansing and conditioning compositions are disclosed comprising comprising; a) from 1% to 50% by weight of a cleansing surfactant, b) discrete, dispersed droplets comprising a water-insoluble silicone conditioning oil characterised in that the mean diameter of the droplets (D3,2) is from 2 to 100 micrometres and c) a...

20060057090 - Cosmetic preparations with anitacterial properties: Disclosed are cosmetic preparations and, more particularly, skin and hair care and cleaning products with an amount of at least one glycyrrhetic antibacterial agent selected from glycyrrhetic acid, glycyrrhetic acid derivatives and extracts of Glycyrrhiza glabra, and their salts, effective to inhibit or prevent the growth of bacteria. The cosmetic...

20060057092 - Cosmetic use of a composition including an ascorbic acid compound and polyamide particles: The present invention relates to the cosmetic use, for the care of greasy skin, of a composition including, in a physiologically acceptable medium, (a) at least one water-soluble ascorbic acid compound and (b) porous polyamide particles having a mean diameter, by volume, of less than or equal to 10 μm,...

20060057091 - Semitransparent cosmetics: A semitransparent cosmetic consisting of an O/W emulsion which comprises (a) a ceramide, (b) an oil component, (c) a nonionic surfactant, and (d) water and has a mean particle diameter of 100 to 300 nm; a semitransparent cosmetic as described above wherein the component (c) is polyoxyethylene hydrogenated castor oil;...

20060057093 - Preparation for topical use with the function of combating hair loss: A preparation for topical use containing benzyl nicotinate and having the function of combating and/or delaying hair loss, whose composition comprises:—two amino acids, hydroxyproline and aspartic acid, complexed with a silanol,—an enzyme activator, comprising octyl butyrate is described....

20060057094 - Hair styling composition comprising at least one hydrophilic polymeric high porosity material and at least one fixing polymer: Described herein is a hair styling composition comprising, in a physiologically acceptable liquid medium: at least one hydrophilic polymeric high porosity material, and at least one fixing polymer, with the proviso that the at least one hydrophilic polymeric high porosity material is not a silicone polymer or an alkyl polymethacrylate...

20060057095 - Cosmetic composition comprising at least one cationic surfactant, at least one cationic polymer, at least one fatty alcohol, and at least one diol: Disclosed herein is a cosmetic composition, for example, a hair composition, comprising, in a cosmetically acceptable medium, at least one cationic surfactant, at least one cationic polymer, at least one fatty alcohol, and at least one diol comprising 6 carbon atoms, wherein the total concentration of the at least one...

20060057098 - Photoreactive polysaccharide, photocrosslinked polysaccharide product and method of making same and medical materials made from the crosslinked polysaccharide: A photoreactive polysaccharide which comprises a polysaccharide bound to a glycidyl ester via a covalent bond, a photocrosslinked-polysaccharide prepared by using the photoreactive polysaccharide, and medical products comprising the photocrosslinked-polysaccharide....

20060057099 - Ph-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy: Conjugates consisting of a polymeric carrier constituted by 30 to 3,000 monomer units linked to form a polymeric chain, composed of a) 60 to 99% of N-(2-hydroxypropyl)methacrylamide units, b) 1 to 25% of units of methacryloylated hydrazones of α-amino acids, ε-amino acids, aromatic amino acids or oligopeptides terminated with a...

20060057100 - Composition for attracting blood sucking arthropods and fruit flies: The present invention is directed to a composition for attracting blood sucking arthropods and fruit flies. Furthermore, the present invention is directed to a method of attracting blood sucking arthropods and fruit flies and to a kit or trap, comprising the components of said composition....

20060057101 - German cockroach attractant: e

20060057103 - Antagonists of interleukin-15: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15Rα-subunit and that are incapable of transducing a signal through either the β- or γ-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against...

20060057102 - Mutant interleukin-15-containing compositions and suppression of an immune response: The invention features methods of treating patients who have received, or who are scheduled to receive, a heart, lung, or heart-lung transplant by administering to the patient an agent that antagonizes IL-15 or the IL-15 receptor (IL-15R)....

20060057104 - Methods for stimulating tlr irf3 pathways for inducing anti-microbial, anti-inflammatory and anticancer responses: The present invention provides methods for stimulating Toll-like receptors (TLR) to activate IRF (e.g., an IRF3) and signaling pathway, and thereby directing an antimicrobial activity. The present invention also provides methods for identifying agents that bind and/or stimulate TLR and mediate induction of an IRF3 pathway, thereby directing an antimicrobial...

20060057105 - Methods of treating ocular inflammation and allergy: The present specification discloses methods of treating ocular inflammation and ocular allergy through the administration of interferon inhibitors to a mammal, including a human, in need thereof....

20060057106 - Freeze-dried interferon-y composition for transpulmonary administration and inhalation system therefor: The present invention provides a freeze-dried interferon-γ composition for transpulmonary administration which can maintain IFN-γ stably, and can be prepared into fine particles in a vessel at the time of use. A freeze-dried interferon-γ composition for transpulmonary administration of the present invention has the following properties (i) to (iv): (i)...

20060057107 - Combination treatment for multiple sclerosis: The present invention provides for the treatment of multiple sclerosis by combination therapies of CD52 specific antibodies, such as CAMPATH-1H, with either a Type 1 interferon or coploymer-1....

20060057110 - Antigen-presenting cells for neuroprotection and nerve regeneration: Pharmaceutical compositions and methods for preventing or inhibiting neuronal degeneration, or for promoting nerve regeneration, in the central nervous system (CNS) or peripheral nervous system (PNS), in the treatment of an injury, disorder or disease of the CNS or PNS, comprise antigen-presenting cells, preferably dendritic cells, that have been pulsed...

20060057112 - Macrophage derived chemokine (mdc), mdc analogs, mdc inhibitor substances and uses thereof: The present invention provides purified and isolated polynucleotide sequences encoding a novel macrophage-derived C-C chemokine designated “Macrophage Derived Chemokine” (MDC), and polypeptide fragments and analogs thereof. Also provided are materials and methods for the recombinant or synthetic production of the chemokine, fragments, and analogs; and purified and isolated chemokine protein,...

20060057109 - Method of using anti-apoptotic factors in gene expression: The present invention is directed to methods of prolonging the expression of a heterologous gene (transgene) in a cell, preferably a malignant cell. This method can be used to increase the concentration of a chemotherapeutic agent in a target cellular environment. Preferably, the present invention relates to methods of inhibiting...

20060057111 - Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent: The present invention relates to methods of treating mammals affected by, for example, a hyperproliferative disease such as cancer, by administering a tumor-targeted superantigen and a chemotherapeutic agent, whereby the administration of the tumor-targeted superantigen and chemotherapeutic agent reduce the antibody response and enhance the T cell response. The superantigen,...

20060057108 - Use of urea-adjuvated polypeptides for diagnosis, prophylaxis and treatment: The invention relates to a method for infiltration of polypeptides in cells. The invention further relates to the use of the cells and urea-adjuvated polypeptides for the diagnosis, treatment or prevention of diseases. The invention further relates to the detection of polypeptide-specific immune cells....

20060057114 - Methods of using vectors to treat metabolic disorders: Isolated nucleic acid-based vectors and lentivirus vectors, and methods of using those vectors to inhibit or prevent metabolic disorders in a mammal, are provided....

20060057113 - Novel adenoviruses, nucleic acids coding therefor, and use thereof: The present invention is related to an adenovirus expressing a first protein which is selected from the group comprising an E1B protein and an E4 protein, priorto a second protein which is selected from the group comprising an E1A protein....

20060057115 - Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polynucleotides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations...

20060057116 - Recombinant influenza viruses for vaccines and gene therapy: The invention provides a composition useful to prepare influenza A viruses, e.g., in the absence of helper virus....

20060057117 - Vascular endothelial growth factor 2: Disclosed are human VEGF-2 polypeptides, biologically active, diagnostically or therapeutically useful fragments, analogs, or derivatives thereof, and DNA(RNA) encoding such VEGF-2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides and polynucleotides may be used therapeutically for stimulating...

20060057127 - Cytokine-expressing cellular vaccines for treatment of prostate cancer: Genetically modified cytokine-expressing cells for use as vaccines in the treatment of prostate cancer are provided. More specifically, genetically modified, GM-CSF expressing cells as a means to generate an enhanced immune response to beta filamin and the use thereof in the treatment of prostate cancer are described....

20060057128 - Intradiscal injection of autologous interferon: Administering to a patient Type I interferon or viable cells induced to produce Type I Interferon preferably into an inflamed joint, such an interverebral disc, for example, is disclosed....

20060057130 - Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna: Disclosed are cells and methods for treating or preventing tumor formation or infections with pathogens in a patient. The cells of the invention are antigen-presenting cells (e.g., dendritic cells or macrophage) that have been loaded with RNA derived from tumors or pathogens. By administering the RNA-loaded antigen-presenting cells to a...

20060057129 - Preloaded dendritic cell vaccines for treating cancer: This disclosure provides a technology for making a dendritic cell vaccine suitable for high volume manufacturing and distribution. Human stem cells are differentiated in a multi-step protocol to generate cell populations bearing a dendritic cell phenotype. The cells are loaded by pulsing with a specific tumor antigen, or by activation...

20060057118 - Feed composition for ruminants: A feed composition for ruminants comprising a microbe having nitrite reductase activity, wherein said microbe has been modified so that intracellular nitrite reductase activity is enhanced is disclosed. A feed composition for ruminants comprising a microbe having nitrite reductase activity, wherein said microbe is selected from the group consisting of...

20060057132 - Identifying and treating vaginal infections: The presence of a vaginal affection is determined in a subject using an identifiable indicator and, if the indication is positive, a gynecological composition comprising one or more Lactobacillus strains is administered locally in an amount effective to treat the vaginal affection. Also described are packages or kits including a...

20060057131 - Malleable protein matrix and uses thereof: The present invention relates to a malleable protein matrice (MPM), which is the reaction product of the agglomeration of proteins after a fermentation process and is exhibiting biological activities and is suitable for the incorporation (or encapsulation) of various hydrophilic or lipophylic substances. The present invention also relates to the...

20060057120 - Administration of dendritic cells partially matured in vitro for the treatment of tumors: The present invention provides populations of cells comprising partially matured dendritic cells that can be used for administration individuals having a tumor. Partially matured dendritic cells, those contacted with a dendritic cell maturation agent for about 1 to about 10 hours, or more, efficiently take up and process tumor antigens...

20060057119 - Biologic skin repair and enhancement: Muscle cell materials and methods are provided for refurbishing skin. Skin surfaces are prepared by removing dead cells and myoblasts are added in a cell-nutritive solution. An embodiment provides autologous human myoblast cells from the individual to be treated, serum from the individual, and an angiogenesis factor for stimulation of...

20060057121 - Compositions and treatments using ex vivo activated cells for myelosuppressed patients: The disclosure includes protocols for activating and administering human blood cells to severely myelosuppressed patients, including patients treated for cancer, e.g., by chemotherapy or radiation. The protocol may include culturing blood cells in the presence of activating agents, for example, a cytokine and an ionophore....

20060057126 - Device and method for hair growth from stem cells: A method for utilizing an individual's undifferentiated papilla and/or bulge area stem cells to stimulate hair growth. The inventor has discovered that bulge area stem cells can be harvested, isolated, cloned, and successfully transplanted into an area of the donor's skin where increased growth of hair is desired to increase...

20060057122 - Functional assessment, specific enrichment and specific depletion of alloreactive human t cells: Alloreactive immune cell populations, clinical uses thereof and a means for specifically depleting alloreactive immune cells, while sparing other immune cell populations and thereby retaining broad specificity for other immune stimuli are disclosed. The present disclosure relates a means for specifically depleting alloreactive T cells, while sparing other T cell...

20060057125 - Liver stromal cells for prevention and treatment of immune responses in transplantation: The present invention encompasses methods and compositions for reducing an immune response to a transplant in a recipient by treating said recipient with an amount of liver stromal cells effective to reduce or inhibit host rejection of the transplant. Also disclosed is a method of inducing a reduced immune response...

20060057123 - Method of inducing memory b cell development and terminal differentiation: A method is disclosed herein for inducing differentiation of a B cell progenitor into a memory B cells and/or a plasma cell. The method includes contacting a population of cells including a mature B cell or a B cell progenitor with an effective amount of IL-21, and isolating memory B...

20060057124 - Methods and compositions for culturing cardiomyocyte-like cells: The present invention provides cardiomyocyte-like cells that have been cultured from populations of bone marrow cells. The culture method includes the use of defined media that are free of agents such a 5-azacytidine. The cardiomyocyte-like cells can be engrafted to heart tissue to repair damage resulting from an ischaemic episode....

20060057133 - Topical pathogenic-tissue-destroying liquid: The invention relates to a method of producing a pharmaceutical composition, consisting in mixing nitric acid in composition with mucin and ptyalin enzymes which are used as absorbers. Together, said components produce a topical aqueous solution which destroys pathogenic tissue, by coagulating same, in order to treat a patient with...

20060057134 - Antibody against antibacterial peptide and utiliazation thereof: An antibody which binds to a “peptide consisting of the amino acid sequence represented by SEQ ID NO:1”, and a method for assaying a “peptide comprising the amino acid sequence represented by SEQ ID NO:1” in a sample and a method for detecting a bacterial pneumonia, wherein the methods use...

20060057135 - Mucosal vascular addressins and uses thereof: The present invention relates to pharmaceutical compositions which comprise an antibody and/or antigen-binding fragments which have the epitopic specificity of ACT-1 monoclonal antibody....

20060057136 - Immunotherapy of b-cell malignancies using anti-cd22 antibodies: B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects....

20060057140 - Anticoagulant agents useful in treatment of thrombosis: Monoclonal antibodies directed against coagulation factors and their use in inhibiting thrombosis are disclosed....

20060057141 - Compositions and methods for the therapy and diagnosis of ovarian cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides....

20060057137 - Glp-1 and methods for treating diabetes: The present invention relates to use of GLP-1 or a related molecule having GLP-effect for the manufacture of a medicament for preventing or treating diabetes in a mammal. The amount and timing of administration of said medicament are subsequently reduced to produce a “drug holiday”. Practice of the invention achieves...

20060057139 - Process for producing humanized chimera antibody: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed....

20060057138 - Tie complex binding proteins: Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity and angiogenesis. The agents can be used to...

20060057142 - Biocompatible devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood: Devices, systems, and methods reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce...

20060057143 - Diagnostics and therapeutics for diseases associated with chemokine receptor 11 (ccr11): The invention provides a human CCR11 which is associated with the disorders of the peripheral and central nervous system, cardio-vascular diseases, genitourinary diseases, metabolic diseases and hematological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and...

20060057144 - Fc receptor modulators and uses thereof: This invention relates to a method of inhibiting FC receptor binding of immunoglobulin comprising the use of a Fc receptor modulating compound which binds to defined surfaces on a Fc receptor. The present invention also relates to a method for treating a variety of diseases using a Fc receptor modulating...

20060057145 - Methods to prevent tumor recurrence by blockade of tgf-beta: Methods are provided herein to prevent a tumor recurrence in a subject, involving administering to the subject an agent that blocks the TGF-β signaling pathway. In one embodiment, the agent inhibits the immunosuppressive effects of TGF-β. Also provided is a method of enhancing an immune respond in a subject to...

20060057147 - Antibody recognizing antibody: An antigen having a part which is exposed on the surface of a cell at the formation of a tumor mass, and a pharmaceutical composition and a labeling agent comprising a ligand which recognizes the antigen....

20060057148 - Compositions and methods for treatment of non-hodgkin's lymphoma: The present invention is directed to compositions of matter useful for the treatment of non-Hodgkin's lymphoma in mammals and to methods of using those compositions for the same....

20060057146 - Selective targeting of tumor vasculature using antibody molecules: The present invention relates to selectively targeting tumoral vasculature in vivo using a human recombinant scFv, L19, to the angiogenesis marker ED-B domain of fibronectin. In preferred embodiments, a complete human IgG1 is employed having the variable regions of L19. In other embodiments is employed a mini-immunoglobulin generated by fusing...

20060057149 - Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof: The present invention relates to compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV) and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV) infection utilizing said...

20060057151 - Bmpb novel nucleotide and amino acid sequences and diagnostic and therapeutic uses thereof: An isolated amino acid sequence comprising the sequence set out in SEQ ID NO:2 or an amino acid sequence substantially homologous thereto, or a fragment thereof, with the proviso that the amino acid sequence in SEQ ID NO:3 is specifically excluded....

20060057150 - Compositions against chicken coccidiosis: Prevention and treatment of coccidiosis in chicken is accomplished by administering an anti-chicken coccidiosis composition adapted for oral administration. This composition contains an antibody obtained from an egg of a chicken immunized with an antigenic outermembrane protein or an immunogenic fragment thereof as an antigen having an immunogenicity common for...

20060057152 - Helicobacter system and uses thereof: Helicobacter based preparations comprising a pharmacologically active molecule of interest are disclosed, as well as methods of preparing and using said preparations. In particular, Helicobacter pylori vectors, vector plasmids and recombinant cells that include a sequence encoding a pharmacologically active molecule of interest useful in therapeutic treatments and/or vaccination against...

20060057154 - Compositions for inducing of immunotolerance: Described are methods of treating allergic disorders and compositions for use therein. The methods comprise administering an allergen and one or more medicaments. These medicaments are compounds that inhibit the transcription of genes involved in the initiation of innate and specific immunity, thereby promoting the development of tolerance to these...

20060057153 - Method and composition for the inhibition of mitosis: A function for the human protein, Bsh3 was identified herein as being involved in mitosis. Thus, inhibitors of Bsh3 can be used for the treatment of cancer or other diseases marked by over-proliferation. Inhibitors of the yeast homolog (S. pombe Bsh3) can be used as anti-fungals. Alternatively, Bsh3 or Bsh3...

20060057155 - Adp-ribosylating bacterial toxins: ADP-ribosylating toxins from Neisseria meningitidis, Streptomyces coelicolor, Mycoplasma pneumoniae, Salmonella typhimurium Salmonella paratyphi, and Streptococcus pyogenes are disclosed, together with mutant toxins and uses therefor. There is only a low level of sequence identity between these toxins and toxins such as cholera toxin and E. coli heat labile toxin....

20060057156 - Materials and methods for inductions of immune tolerance: The invention provides methods of inducing immune tolerance to target antigens in individuals seropositive for certain infectious agents by administration of epitopes derived from those infectious agents. Epitopes derived from viruses which carry homologues of interleukin 10 (IL-10) in their genome, such as Epstein Barr Virus and cytomegalovirus, are particularly...

20060057157 - Mushroom extracts having anticancer activity: The invention relates to a method for treatment of chronic myelogenous leukemia (CML), Ph+ acute lymphoblastic leukemia (ALL), prostate cancer and β-globin disorders such as sickle cell anemia and β-thalassemia, comprising administration of a mycelium extract from at least one higher Basidiomycetes medicinal mushroom selected from the group consisting of...

20060057159 - Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease: The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus alone or in addition to...

20060057158 - Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines: Chimeric human-bovine respiratory syncytial virus (RSV) are infectious and attenuated in humans and other mammals and useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric RSV genome or antigenome which includes a partial or complete human or bovine...

20060057160 - Vaccine composition: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are less phase variable in terms of their LOS immunotype, and from which novel LOS subunit...

20060057161 - Detection of coronavirus infection: Isolated polypeptides containing one of SEQ ID NOs: 1-11. Also disclosed are (i) isolated nucleic acids encoding the polypeptides and related expression vectors and host cells; (ii) purified antibodies that recognize the polypeptides; and (iii) methods of producing the polypeptides, diagnosing infection with a coronavirus, and producing the antibodies....

20060057162 - Induction of cytotoxic t-lymphocyte responses: Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing a microfluidized antigen formulation which comprises, consists, or consists essentially of...

20060057163 - Live recombined vaccines injected with adjuvant: The recombinant live vaccine comprises a viral vector incorporating and expressing in vivo a heterologous nucleotide sequence, preferably a gene of a pathogenic agent, and at least one adjuvant compound chosen from the acrylic or methacrylic polymers and the copolymers of maleic anhydride and an alkenyl derivative. It is in...

20060057164 - Novel hcv non-structural polypeptide: Polypeptides comprising a mutant non-structural Hepatitis C virus useful in diagnostic and/or immunogenic compositions are disclosed, in which the mutant is an N-terminal mutation that functionally disrupts the catalytic domain of NS3. Polynucleotides encoding these polypeptides, host cells transformed with polynucleotides and methods of using the polypeptides and polynucleotides are...

20060057165 - Clostridium botulinum toxin formulation and method for reducing weight: A method of altering taste sensation in an individual is provided, the method comprising administering an effective amount of botulinum toxin to the taste cells of the individual. The method can be used to effect reduced caloric consumption in an individual in need of reduced caloric consumption or to effect...

20060057166 - Methods for treating raynaud's syndrome: Methods for treating Raynaud's syndrome by administering a botulinum toxin directly to an afflicted tissue of a patient....

20060057168 - Microemulsion process and composition: There is provided a process for the preparation of an oil in water (O/W) microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, the method including the steps of a) Admixing a first part including at least one of the group consisting of animal,...

20060057167 - Stable lipophilic emulsions for acrylic coating and method of making: Emulsions of lipophiles such as glycerol monostearate which are compatible with acrylic copolymer emulsions are made stable by using an emulsion stabilizer such as polysorbate 80 in an amount by weight between 1 % and 5% of the lipophile and homogenizing the emulsion wherein the emulsion micelles are less than...

20060057170 - Oil-in-water emulsion containing fillers: A composition for topical application in the form of an oil-in-water emulsion containing an oily phase dispersed in an aqueous phase, the globules of oily phase of which have a mean diameter ranging from 50 to 200 nm, prepared without introduction of mechanical or thermal energy and exhibiting good stability...

20060057169 - Topical anhydrous delivery system for antioxidants: This invention relates to an anhydrous composition comprising an antioxidant comprising over 40% by weight of hydrolysable tannins having molecular-weight of less than 1,000 and a substantially anhydrous or non-aqueous liquid vehicle functioning to disperse the antioxidant. The composition is suitable as cosmetic composition and/or therapeutic and/or prophylactic composition and/or...

20060057171 - Solitonium and textile having solitonium for weight reduction: A solitonium having the average particle size of about 5 μm is made up of the sericite mineral of about 40% by weight; the agalmatolite mineral of about 39.7% by weight; the zeolite mineral of about 10% by weight; the montmorillonite mineral of about 10% by weight; and the GeO2...

20060057175 - Broad spectrum preservation blends: A composition having effective broad spectrum preservation activity comprising a mixture of caprylyl glycol or one or more analogs thereof, or mixtures thereof with a preservative selected from the group consisting of: (1) chloroxylenol and 2-phenoxyethanol, (2) chloroxylenol and chlorphenesin, (3) chlorphenesin and 2-phenoxyethanol, and (4) chloroxylenol, chlorphenesin and 2-phenoxyethanol....

20060057176 - Easy-to-use biocidal/virucidal compositions: A tableted biocidal/virucidal composition comprising (a) 0.01 to 5 parts by weight of a water soluble inorganic halide, (b) 25 to 60 parts by weight of an oxidizing agent, (c) 3 to 8 parts by weight of sulfamic acid, (d) up to about 10 parts by weight of an anhydrous...

20060057173 - Insecticide compositions and process: wherein R is a linear alkyl group of from approximately 0 to 15 carbon atoms and X has an average value from about 1 to 3; and b) an insecticide selected from the group consisting of nicotinoids, chlorfenapyr, pyrethrum and piperonyl butoxide. Such compositions are effective against a wide range...

20060057172 - Liquid animal repellant containing oils of black pepper and capsicum: The present invention provides a novel liquid animal repellant composition which is environmentally safe, non-toxic, long-lasting and efficacious against a wide of animals such as dogs, cats, raccoons, skunks, mice, rats, squirrels, chipmunks, deer, etc....

20060057174 - Natural-non-toxic insect repellant: The present invention provides an insect repellant solution comprising between 0.3 and 0.7 percent by weight rosemary oil, between 0.05 and 0.3 percent by weight citronella oil and between 0.1 and 0.3 percent by weight table salt. There may also be between 0.07 and 0.7 percent by weight mint oil,...

20060057177 - Sustained releaser comprising sex pheromone substances and pest control method: Provided are a sustained releaser of sex pheromone substances and a method for controlling insect pest by using the releaser, each enabling to control the simultaneous release of a mixture of sex pheromone substances having different chemical structures of one insect pest or a mixture of sex pheromone substances of...

20060057178 - Novel pest control methods: Certain embodiments of the methods and compositions of matter disclosed herein relate to: “simultaneous” control of rodents and at least one insect pest (e.g., cockroach, ant, tick) using the same bait; control of ticks by orally administering to mammals a diet composition comprising fipronil; enhancing insecticide efficacy through use of...

20060057179 - Therapeutic polyesters and polyamides: Polymers (i.e. polyesters, polyamides, and polythioesters or a mixture thereof) which degrade hydrolytically into biologically active compounds are provided. Methods of producing these polymers, intermediates useful for preparing these polymers, and methods of using these polymers to deliver biologically active compounds to a host are also provided. Medical implants based...

20060057180 - Tunable nonfouling surface of oligoethylene glycol: An article having a nonfouling surface thereon is comprises: (a) a substrate having a surface portion; (b) a linking layer on the surface portion; and (c) a polymer layer formed on the linking layer, preferably by the process of surface-initiated polymerization of monomeric units thereon, with each of the monomeric...

20060057182 - Flexible bioresorbable hemostatic packing and stent having a preselectable in-vivo residence time: The invention provides a flexible bioresorbable foam having hemostatic properties and a preselectable in-vivo residence time. The foam includes a blend of collagen and a hyaluronic acid component such as hyaluronic acid or a derivative thereof, typically, the hyaluronic acid component is present in a range of from about 70...

20060057181 - Method for determining the gastric evacuation using a 13c-labelled test meal: The method for determining the gastric emptying by orally administering a test substance and measuring its dwelling time in the stomach comprises determining the increase of 13CO2 in the exhaled respiratory air before and after the oral administration of free 13C-octanoic acid together with a standardized test meal....

20060057183 - Indwelling stent: As a therapy for angiostenosis, angioplasty (PTA, PTCA), in which a small balloon is inflated in a blood vessel to expand the vessel, has been widely practiced as a minimally invasive treatment. In this therapy, however, repeated stenosis (restenosis) occurs at a high incidence. In order to reduce the restenosis...

20060057184 - Process to treat avascular necrosis (avn) with osteoinductive materials: A method of treating avascular necrosis (“AVN”) comprising administering one or more osteoinductive formulations to the site of AVN disease progression. The method involves the combination of a core decompression technique, followed by the introduction of one or more osteoinductive formulations into the decompression core, and concluding with capping of...

20060057185 - Composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person: Arachidonic acid and/or compounds containing arachidonic acid as a constituent fatty acid are used to obtain compounds which prevent decline of, improve or enhance normal responses of cognitive abilities of a healthy person, and which are highly suitable for pharmaceuticals as well as food products, with minimal side effects....

20060057188 - Dietary supplement energy-providing to skeletal muscles: Dietary supplements—providing energy and strengthening skeletal muscles and facilitating skeletal muscles ability to sustain prolonged periods of physical activity—containing propionyl-L-carnitine or one of its salts, coenzyme Q10, nicotinamide, riboflavin, pantothenic acid and optionally other components such as amino acids and creatines....

20060057187 - Emulsions containing unsaturated fatty acids and esters thereof: The disclosed invention relates to emulsions containing, based on the total weight of the emulsion, a) 0.1 to 50% by weight of a conjugated linoleic acid or derivative thereof, b) 0.1 to 30% by weight of a vegetable lecithin mixture, c) 0 to 20% by weight of a co-emulsifier, d)...

20060057186 - Oral contraceptive multivitamin compound and methods of administration: A pharmaceutical preparation comprising progestin, estrogen and a multivitamin agent. The progestin may be between 0 and 0.50 mg Desogesterel and the estrogen may be between 0 and 0.2 mg Ethinyl Estradiol. The multivitamin agent may be any combination of alpha carotene, beta carotene, biotin, bioflavonoid, calcium, chasteberry fruit, chromium,...

20060057189 - Aqueous crop protection formulations comprising asulam: A medicated patch for extracting bee/wasp sting toxins from the human skin includes a flexible substrate layer that has a planar adhesive surface and an annular shape. An annular receptacle is centrally registered on the adhesive surface and is permanently affixed to the substrate layer. A poultice is nested on...

20060057190 - Silicone topcoat with improved dirt repellency and improved bondability: m

20060057191 - Biocidal fibrous and film materials utilizing silver ion: Disclosed are compositions comprising a hydrophilic polymer, a hydrophobic polymer, and a silver ion, wherein the silver ion associates with at least one hydrophilic or hydrophobic polymer, and wherein the composition does not comprise an effective amount of a chlorite ion. Also disclosed are methods of making a photo-stable silver...

20060057194 - Cationic liposomes for gene transfer: The present invention relates to synthetic cationic lipids, liposome formulations and the use of such compounds to introduce functional bioactive agents into cultured cells....

20060057193 - Delivery system for pharmaceutical agents: The present invention relates to a delivery system for pharmaceutical agents. Said delivery system comprises liposomes which comprise in their internal compartment a pharmaceutical agent to be delivered and which have linked to their external surface the cell adhesion molecule NCAM or a fragment thereof. In a preferred embodiment said...

20060057192 - Localized non-invasive biological modulation system: The present invention provides methods for non-invasive localized delivery of biologically active molecules, comprising packaging a molecule(s) of interest inside a thermosensitive particle, administering said particles to a subject, and inducing localized release of said molecules from said particles using a focused heat source. The thermosensitive particles may be thermosensitive...

20060057196 - Efavirenz tablet formulation having unique biopharmaceutical characteristics: The present invention provides an efavirenz tablet formulation which, when administered as a single dose to a subject, provides a mean maximum plasma concentration (Cmax) of about 4 μM to about 14 μM, a mean time of maximum plasma concentration (Tmax) of about 2 hours to about 5 hours, and...

20060057195 - Stable solid preparations: It is intended to provide a process for producing unstable amorphous benzimidazole compounds having a proton pump inhibitor function, and stable solid preparations for medicinal use containing these compounds which are produced by blending such an amorphous benzimidazole compound with a nontoxic base such as a basic inorganic salt, forming...

20060057197 - Pharmaceutical dosage forms having immediate release and/or controlled release properties: The present invention relates generally to pharmaceutical dosage forms comprising: an absorption window active agent; a controlled release component comprising enteric-coated controlled release beads, wherein the enteric-coated release beads comprise at least two pH-sensitive polymer layers. The controlled-release dosage forms provide good bioavailability of absorption window active agents....

20060057198 - Drug delivery from embolic agents: A pharmaceutical composition for uterine fibroid embolisation comprises a polymer and, associated with the polymer in a releasable form, a COX inhibitor, e.g. a non-steroidal anti inflammatory drug, such as ibuprofen. The polymer is preferably in particulate form, such as in the form of microspheres. A suitable polymer is a...

20060057199 - Orally disintegrating tablets of atomoxetine: A coated multi-particulate pharmaceutical dosage form such as an orally disintegrating tablet (ODT) presentation for delivering atomoxetine or a pharmaceutically acceptable salt thereof, a selective norepinephrine reuptake inhibitor indicated for the treatment of ADHD, into the body to maintain a therapeutically effective amount of atomoxetine in the plasm. The dosage...

20060057200 - Tablets with site- and time-controlled gastrointestinal release of active ingredient: The present invention describes a pharmaceutical dosage form with site- and time-controlled gastrointestinal release of active ingredient....

20060057201 - Multicomponent pharmaceutical dosage form: A multi-component pharmaceutical dosage form suitable for retaining drug substance can be released to provide a controlled drug release profile in the gastro intestinal environment, characterized by a body e.g. comprising a delayed release polymeric material such as Eudragit 4135F, the body having at least one cavity said cavity having...

20060057203 - Modified release formulations of oxcarbazepine and derivatives thereof: Oral once a day dosage forms comprising oxcarbazepine are disclosed....

20060057202 - Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them: A novel patient-convenient, cost effective pharmaceutical composition, comprising of thiazolidinediones and biguanide for controlling hyperglycemia manufactured as multilayer tablet and its process of manufacturing, for immediate release of thiazolidinediones or thiazolidinediones and biguanide and prolonged release of the biguanide only, the tablet comprising of minimum two layers wherein one outer...

20060057204 - Pharmaceutical compositions containing venlafaxine: The invention provides a delayed burst release formulation comprising a core formed as a compressed tablet and an outer coating that surrounds the core; said core comprising venlafaxine, or a pharmaceutically acceptable salt thereof, at least one burst controlling agent and a disintegrant; and said outer coating comprising a water...

20060057205 - Phenylepherine containing dosage form: A pharmaceutical dosage form which comprises phenylepherine or a pharmaceutically acceptable salt thereof and a second drug. The dosage form provides a plasma concentration within the therapeutic range of the second drug over a period which is coextensive with at least about 70% of the period over which the dosage...

20060057206 - Controlled release nanoparticle active agent formulation dosage forms and methods: Controlled release of self-dispersing nanoparticle active agent formulations is provided by dispersing porous particles into which have been sorbed a self-dispersing nanoparticle active agent formulation in osmotic, push-layer dosage forms. The dosage forms may provide for continuous or pulsatile delivery of active agents....

20060057207 - Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene: A fast disintegrating dosage form of varenicline comprising an effective amount of varenicline or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the dosage form disintegrates in a patient's oral cavity in less than three minutes. Also provided are a method for reducing nicotine addiction,...

20060057208 - Biocompatible drug delivery apparatus and methods: Apparatus and methods for treatment of an internal cavity are provided. The internal cavity is coated with a treatment solution. The treatment solution can include a solidifiable matrix with or without a drug or combination of drugs incorporated therein, or a drug solution without a solidifiable matrix. The treatment solution...

20060057210 - Controlled release oxycodone compositions: A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation...

20060057211 - Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex: A particle including a matrix-forming agent and a polyelectrolyte-amphiphilic agent adduct wherein the polyelectrolyte-amphiphilic agent adduct is in physical communication with the matrix-forming agent. The particle further includes a coated magnetic field-responsive agent and a biomaterial. Methods of making the particle are provided. Also provided are methods of delivery of...

20060057209 - Methods, compositions and devices, including microfluidic devices, comprising coated hydrophobic surfaces: Methods are disclosed for coating at least a portion of a hydrophobic surface, including the surfaces of plastics or other polymers. Such methods include the use of a first coating layer and/or region that interacts with the hydrophobic surface, although the formation of a chemical bond between the first coating...

20060057212 - Polyolefin additive composition comprising 3,4-dimethyl dibenzylidene sorbitol and p-methyl dibenzylidene sorbitol and method of using such composition in a polyolefin: A specific combination of two different polyolefin clarifying and nucleating agents, namely 3,4-dimethyldibenzylidene sorbitol and p-methyldibenzylidene sorbitol is provided. Such a combination surprisingly provides improved clarification and crystallization temperatures to polypropylene articles and formulations, better than bis-p-methyldibenzylidene sorbitol alone and equivalent or better than 3,4-dimethyldibenzylidene sorbitol. Such a combination of...

20060057217 - Aqueous, non-alcoholic liquid powder formulations: The present invention is an aqueous, non-alcoholic liquid powder formulation. The aqueous, non-alcoholic liquid powder formulation comprises from about 14% to about 75% by weight of the formulation of water, from about 25% to about 60% by weight of the formulation of a powder, from about 0.05% to about 1%...

20060057213 - Drug delivery particles and methods of treating particles to improve their drug delivery capabilities: A first embodiment of the invention provides a method of engineering changes in the morphological, chemical or physical features of a particle, to promote, for example, the formation of hairs and pores on the surface of the particle. The presence of these engineered features facilitating the delivery of agents to...

20060057216 - Low-obscuration image transmitting particulate ocular therapeutic formulations: Low-obscuration image transmitting particulate ocular therapeutic formulations are described. Additionally, methods are described for producing and for using such low-obscuration image transmitting particulate ocular therapeutic formulations....

20060057215 - Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility: Methods are described for forming nanoparticle- and microparticle-sized drug delivery agents. Also described are methods for incorporating one or more active therapeutic agents uniformly or non-uniformly within the particles and uses thereof....

20060057218 - Novel composition: A pharmaceutical composition comprising N-[(1-nbutyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide (SB 207266) or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable carriers, wherein at least some of the SB 207266 or salt thereof is in granulated form. Preferably, a filler and/or binder are also present....

20060057214 - Process for the produciton of cross-linked gelatin beadlets: The invention provides a process for the production of cross-linked beadlets containing one or more active ingredients selected from the group of a fat-soluble vitamin active material, a carotenoid and a polyunsaturated fatty acid, the process comprising treating a dry particulate form at a temperature in the range of from...

20060057220 - Fine spherical particles with satisfactory molecular orientation, spherical microcapsules comprising the same and processes for producing these: The present invention relates to a fine spherical particle having uniform molecular orientation having uniform molecular orientation, which is useful in fine chemical fields or electronic and information fields, such as a functional material and a medical material, using membrane formation of a bicephalic compound; a spherical microcapsule encapsulating a...

20060057219 - Method for preparing a polymer micelle pharmaceutical preparation containing drug for injection: A production method of a preparation containing drug-encapsulating polymer micelles is provided, which comprises dissolving a hydrophilic-hydrophobic block copolymer and a sparingly water-soluble drug in a volatile organic solvent, then removing the solvent, and stirring the residue with water at a temperature not higher than 30° C. to dissolve the...

20060057222 - Method for the production of polymerized nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility: Polymerized drug delivery devices are described. Additionally, methods are described for producing and for using polymerized particles for use as drug delivery devices....

20060057221 - Polymeric microparticulates for sustained release of drug and their preparation methods: The present invention relates to polymeric microparticulates for sustained release of drug and to the process for the preparation thereof. The process of the present invention for preparing polymeric microparticulates based on microcoagulation phenomenon of water-soluble polymer not only improves loading amount of drug but also minimizes initial burst of...

20060057223 - Intradiscal production of autologous interleukin antagonist: Administering a buffy coat and immunoglobulin into a disc to induce the production of interleukin receptor antagonist protein IRAP within the disc is disclosed....

20060057224 - Methods for treating open wounds: A method for treating an open wound, such as a surgical wound, may include preparing a first composition including a platelet poor plasma (PPP), and preparing a second composition including a platelet rich plasma (PRP). A layer of the first composition may be applied within the open wound, and a...

20060057225 - Stable pharmaceutical composition useful for treating gastrointestinal disorders: The present invention provides a pharmaceutical composition comprising at least one pharmaceutically acceptable bismuth-containing compound, at least one pharmaceutically acceptable non-clay-derived suspending agent, and water. The suspension exhibits reduced upward pH drift by comparison with an otherwise similar suspension which comprises a clay-derived suspending agent. Such compositions are useful in...

20060057226 - Red ear drops: My invention, Red Ear Drops, is a combination of povidone-iodine and lidocaine hydrochloride monohydrate. The prior entity, povidone-iodine, is effective against many pathogens which include viruses, bacteria, fungi, protozoa, and yeast. The latter drug, lidocaine hydrochloride monohydrate is an effective all purpose, local anesthetic agent. The combination drug product can...

20060057229 - External skin preparations for suppressing sebum secretion: A drug for external application to the skin, for inhibiting sebum secretion, comprising a matrix metalloproteinase inhibitor....

20060057227 - Throat spray: An orally administered composition for relieving or eliminating snoring is described. The composition generally has four mechanisms of action for combating snoring. The composition includes a tissue-firming or astringent agent to firm up throat tissue. The composition also includes a soothing agent to soothe irritated or inflamed tissues. Also included...

20060057228 - Weight loss composition: The present invention provides a dietary supplement and methods of using the same to promote body weight reduction and/or loss of body fat in a subject, and for the management of obesity. The supplement can further be used to reduce one or more metabolic parameters in a subject, such as...

20060057230 - Tea polyphenols bioavailability enhancement method: Methods for increasing tea polyphenol bioavailability. Dosing conditions, such as fasting for defined periods, result in greater oral bioavailability of free catechins....

20060057231 - Pterostilbene as a new agonist for the peroxisome proliferator-activated receptor alpha isoform: Resveratrol, a stilbenoid antioxidant found in grapes, wine, peanuts and other berries, has been reported to have hypolipidemic properties. We investigated whether resveratrol and its three analogs (pterostilbene, piceatannol and resveratrol trimethyl ether) would activate the peroxisome proliferator-activated receptor alpha (PPARα) isoform. This nuclear receptor is proposed to mediate the...

20060057232 - Method of altering age perception: Methods and compositions for altering perception of age of an individual are disclosed....

20060057233 - Coolant plant extract compositions containing monomenthyl succinate: The present invention relates to plant extracts containing a monomenthyl succinate for use as a coolant in food and non-food products. Methods for isolating the plant extracts are also provided....

20060057234 - Composition comprising pharmaceutical/nutraceutical agent and a bio-enhancer obtained from glycyrrhiza glabra: The invention relates to a new use of a non-alkaloid compound that is plant derived glycoside ‘glycyrrhizin’ as a highly potent bio-enhancer of activity and availability of antibiotics and other drugs including anti-infective and anticancer agents. The molecule of invention facilitates the absorption/uptake of antibiotics and other molecules across the...

20060057235 - Methods of using pomegranate extracts for causing regression in lesions due to arteriosclerosis in humans: Methods of using pomegranate extracts of the present invention for treating patients with atherosclerosis, or increased intima-media thickness of an artery, are provided. The methods comprise the step of administering to the patient a composition comprising a therapeutically effective amount of an extract from pomegranate. The methods of the present...

20060057236 - Process for producing an extract of ivy leaves: A process for producing an extract of ivy leaves using an extracting agent, with the extract comprising α-hederin. In this process, a quantity of dried ivy leaves is first of all comminuted, then fermented by adding water and subsequently extracted by adding the extracting agent; finally, the extract is dried....

20060057238 - Extract of buds of cryptomeria japonica d. don: The invention relates to extract of buds of <i>Cryptomeria japonica D. Don</I> which may be obtained by means of a first solid/liquid extraction stage, followed by a second solid/liquid separation stage and finally a third stage of recovery of the liquid phase....

20060057237 - Extract with anti-tumor and anti-poisonous activity: Extracts of the plant Calotropis procera, having a pharmacological activity, in particular an anti-poisonous activity, and active compounds isolated thereof are described. Furthermore, methods for the extraction of the extracts are disclosed. Also, a pharmaceutical composition or product for the treatment of cancer which includes an effective amount of the...

20060051290 - Short carbon nanotubes as adsorption and retention agents: A method for delivering a radiotherapeutic agent to a target, comprises administering a composition comprising water-soluble nanotubes having an average length less than 50 nm and a radionuclide so as to expose the target to the composition. The nanotubes can be functionalized with a monoclonal antibody having an affinity for...

20060051291 - Synthesis of radiolabeled sugar metal complexes: The invention provides a method for manufacturing or preparing neutral, low molecular weight 99mTc-labeled and 186Re-labeled carbohydrate complexes with an improved radiochemical yield from a simple functionalized sugar, such as glucosamine. In particular the synthesis relies on single ligand transfer (SLT) or double ligand transfer (DLT) reactions for converting a...

20060051292 - Novel self-assembly molecules: There is provided a method of forming a multimeric complex having affinity for a target. The method comprises: obtaining a plurality of self-assembly molecules, said self-assembly molecules including complementary self-assembly units such as verotoxin subunit B, each of which is operatively connected to an interaction domain such as a single...

20060051293 - Amyloid plaque aggregation inhibitors and diagnostic imaging agents: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method...

20060051294 - Method of predicting a diet effect: A method of predicting a diet effect caused by a sympathetic activator includes: making a human ingest the sympathetic activator; obtaining a biological reaction index from the human who has ingested the sympathetic activator; and calculating a predictive value of a diet effect from the biological reaction index based on...

20060051295 - Estrogen receptor interaction with a transcription factor: The invention provides a method to measure a direct interaction between an estrogen receptor and a transactivation protein in an in vitro system by providing for a detection parameter proportionally related to the degree of the interaction, whereby the transactivation protein is c-Rel. In an embodiment of the invention a...

20060051296 - Thickened beverages for dysphagia: The present invention relates to thickened beverage compositions. More particularly the invention relates to beverage compositions thickened for the management of dysphagia. More particularly this invention relates to the production of thickened beverages by a dispensing machine that is also capable of dispensing non-thickened beverages....

20060051297 - Ultrasound contrast agents and process for the preparation thereof: Method for preparing a lyophilized matrix and, upon reconstitution of the same, a respective injectable contrast agent comprising a liquid aqueous suspension of gas-filled microbubbles stabilized predominantly by a phospholipid. The method comprises preparing an emulsion from an aqueous medium, a phospholipid and a water immiscible organic solvent. The emulsion...

20060051298 - Abuse resistent pharmaceutical dosage and method of making same: A pharmaceutical composition includes a therapeutic amount of an active ingredient and at least one gel-forming granule. The gel-forming granule forms a gel when exposed to an aqueous liquid and is coated with an outer coating that is sufficiently brittle so that when the tablet is crushed, a portion of...

20060051300 - Formulations and methods for treating rhinosinusitis: The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory agent having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent....

20060051299 - Nasal pharmaceutical formulations and methods of using the same: Nasal pharmaceutical formulations comprising a drug substance having a specific particle size distribution profile are disclosed herein. Such profile provides increased bioavailability, increased efficacy or prolonged therapeutic effect of the drug substance when administered intranasally. The formulations of the present invention may comprise one or more corticosteroids having a specific...

20060051301 - Coolant solutions and compositions comprising the same: A solution consisting essentially of menthyl lactate and menthol carboxamide dissolved in a solvent, such as propylene glycol, which solvent is acceptable for food, oral care or cosmetic products and a method of preparing it....

20060051303 - Compound protecting against ultraviolet: wherein X represents NH or O; Y′ represents a vinyl group substituted by a methyl group or a phenyl group, or a phenyl group substituted by a methoxy group or a fluorine atom, or a naphthyl group; and Z represents a phenyl group substituted by a methyl group, a carboxyl...

20060051302 - Methods of treating dermal/epidermal junctions and cosmetic preparations for use therein: Methods for protecting, modulating and/or improving the dermal/epidermal junctions of the skin, scalp and/or mucous membranes are described wherein a preparation comprising at least one substance which effects a modulation of one or more dermal/epidermal junction components selected from the group consisting of plectin/HD1, entactin/nidogen, percalan and combinations thereof, is...

20060051304 - Special effects with mixtures of interference pigments: A method of producing mixtures of interference pigments having special effects comprises mixing at least one large particle size interference pigment with at least one normal size interference pigment of predetermined colors and in proportions desired to obtain a unique effect....

20060051305 - Methods of producing lignin peroxidase and its use in skin and hair lightening: Methods of producing lignin peroxidase are provided. Also provided are methods and cosmetic compositions suitable for skin and hair lightening as well as kits and an article-of manufacturing including active ingredients for skin and hair lightening....

20060051306 - Antiperspirant emulsion compositions: A w/o emulsion antiperspirant composition comprising a dissolved antiperspirant salt, an emulsifier and, in a disperse phase separate from the dissolved antiperspirant salt, a polymer comprising Brønsted acid groups....

20060051307 - Oil-based cosmetic preparation: An oil-based cosmetic preparation contains (a) an oily gelling agent, (b) an oil-based ingredient, and (c) at least one selected from the group consisting of ester compounds represented by formula (I) which are reaction products of ditrimethylolpropane with fatty acid, polycondensates of ditrimethylolpropane with polycarboxylic acid, polycondensates of the ester...

20060051308 - Hair detergent compositions: AbstractProvided is a hair detergent composition comprising the following components (a), (b) and (c): (a) an anionic surfactant, (b) a monoalkyl glyceryl ether or monoalkenyl glyceryl ether having a C4-12 alkyl or alkenyl group, and (c) a silicone derivative having a group containing both a hydroxy group and a nitrogen...

20060051309 - Cosmetic dressing containing a waxy cmponent, a film-forming agent and a gel-forming substance: A cosmetic preparation in the form of an O/W emulsion which, besides usual cosmetic ingredients, contains a wax component, a film-forming system and at least one gel component, wherein the gel component has at least one swollen hydrocolloid....

20060051310 - Water-in-oil emulsion comprising a non-volatile non-silicone oil, a cationic surfactant, a polyolefin with polar portion(s), and an alkylmonoglycoside or alkylpolyglycoside: The present invention concerns a cosmetic hair treatment composition, of water-in-oil emulsion type, containing at least one non-volatile non-silicone oil, at least one cationic surfactant, at least one polyolefin with polar portion(s), and at least one of an alkylmonoglycoside and alkylpolyglycoside, and to a cosmetic hair treatment process....

20060051311 - Hair treatment composition containing a combination of at least three different polymers: The hair treatment composition contains a combination of an anionic polysaccharide, a second homopolymer or copolymer, which is built up from acrylamidoalkylsulfonic acids, methacrylamidoalkylsulfonic acids, or their salts, and a third polymer, which is an amphiphilic polymer. Preferably the hair treatment composition is a hair styling gel containing xanthan as...

20060051312 - Multi-layered carbon nanoball for deodorization: Disclosed is a carbon nanoball for deodorization composed of a circular hollow core, and a porous carbon shell to which at least one deodorizing material selected from the group consisting of transition metal, oxidized transition metal and alkali metal salt is adhered. The porous carbon shell of the carbon nanoball...

20060051313 - Cosmetic composition comprising polymers having a star structure, the polymers, and their use: A composition capable of being applied to the hair, comprising, in a cosmetically acceptable medium, at least one polymer with a highly specific ordered structure is disclosed. A process for shaping or retaining the form of the hair using this composition and the use in the formulation of styling products,...

20060051314 - Drug for prevention and/or treatment of constipation and sympton caused by constipation: A medicament for preventive and/or therapeutic treatment of constipation and/or a symptom resulting from constipation which comprises magnesium polycarbophil as an active ingredient. The medicament of the present invention can exhibit high efficacy by promoting a normal defecation without causing a side effect such as a watery stool, an overloose...

20060051315 - Polymers for delivering peptides and small molecules in vivo: Certain hydrophilic polymers, such as a polyoxazoline, when conjugated to a polypeptide or small molecule agent, can enhance the bioavailability of the agent when administered in vivo. Accordingly, hydrophilic polymers of the invention can be used as a delivery vehicle to treat any number of disorders and/or confer a myriad...

20060051316 - Remedy: The present invention relates to a therapeutic agent or prophylactic agent for a disease requiring enhancement of bone morphogenetic protein production or promotion of osteogenesis; an agent for enhancement of bone morphogenetic protein production or an agent for promotion of osteogenesis, a food, beverage or feed for enhancement of bone...

20060051317 - Amphiphilic polymer-protein conjugates and methods of use thereof: Compositions and methods for transporting biologically active proteins and polypeptides, particularly across the blood-brain barrier, are provided....

20060051318 - Medical composition for treating ischemic cardiac failure: The object of the present invention is to provide a pharmaceutical composition for treating non-ischemic heart failure caused by exacerbation of cardiomyopathy. The long-term administration of a colony-stimulating factor ameliorates progressive myocardial fibrosis, left ventricular remodeling and heart failure....

20060051319 - Neuroprotective effect of solubilized udca in focal ischemic model: The present disclosure provides compositions and methods for treating, ameliorating, or relieving at least one symptom associated with loss of blood flow to the brain including, without limitation, ischemic stroke. Compositions of the disclosure may comprise a bile acid compound and a carbohydrate, wherein both materials remain in solution for...

20060051320 - Stable pegylated interferon formulation: The present invention relates to lyophilized formulations of pegylated interferon which are prepared using trehalose as a cryoprotectant. The formulations have a low moisture content, which helps stabilize the pegylated interferon during storage of the formulations at room temperature. In addition, methods for preparing these formulations are provided....

20060051321 - Biological compositions and methods for treatment of testicular cancer: The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthfull benefit in a subject inflicted with testicular cancer. The biological compositions can be used to retard the growth of testicular cancer cells and/or prolonging the time of survival of the subject. The...

20060051322 - Method for therapy of neurodegenerative disease of the brain: A specific clinical protocol for use toward therapy of defective, diseased and damaged cholinergic neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Alzheimer's disease. The protocol is practiced by delivering a definite concentration of recombinant neurotrophin into, or within close proximity of, identified...

20060051333 - Aav virions with decreased immunoreactivity and uses therefor: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2....

20060051335 - Compositions and methods for elimination of unwanted cells: Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium...

20060051332 - Generation of histocompatible tissues using nuclear transplantation: Tissues produced by culture of cells produced by nuclear transfer on a matrix derived from nuclear transfer embryos or embryos and pluripotent cells provided by other methods are provided. These tissues are useful for cell therapy....

20060051334 - Injection of bone marrow-derived conditioned medium for angiogenesis: Methods are provided for promoting formation of collateral blood supply at an ischemic site in tissue by culturing early attaching cells derived from growth of bone marrow aspirate in vitro, collecting early attaching cells produced by the bone marrow culture and injecting conditioned medium produced by culture of the early...

20060051330 - Method for carrying out the ex vivo expansion and ex vivo differentiation of multipotent stem cells: The invention relates to a method for carrying out the expansion of multipotent stem cells ex vivo. Moreover, the invention relates to a two-stage method for carrying out the expansion and differentiation of multipotent stem cells ex vivo, in which it is possible for the stem cells to be gene...

20060051331 - Optimization of transgene expression in mammalian cells: The present invention relates to vectors, compositions and methods for delivering transgenes into mammalian cells. The invention also relates to genetic constructs and recombinant cells suitable to produce such transgenes. The invention more particularly relates to a vector suitable for transgene delivery into mammalian cells, wherein said vector comprises a...

20060051323 - Formulations comprising vitamin b12, method of production and use thereof: Particles comprising a vitamin B12-containing microbial biomass and a solid carrier and compositions comprising said particles and a method for the production of such particles and compositions....

20060051325 - Isolation and use of solid tumor stem cells: A small percentage of cells within an established tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give...

20060051329 - Microfluidic device for the encapsulation of cells with low and high cell densities: Devices and methods for the encapsulation of cells on microfluidic platforms are disclosed. The microfluidic device generally includes a plurality of functional regions to shear, focus, and encapsulate a desired cell or group of cells into a droplet. The microfluidic device can further comprise a polymerization zone to form a...

20060051328 - Mobilization of cells via physical means: A method for treating a patient to repair or regenerate damaged tissue which comprises exposing the patient to an internal physical treatment of the body, for example ultrasound waves or ultra shock waves, MRI or bone surgery so that stem cells, progenitor cells and/or macrophages are released into the bloodstream...

20060051326 - Neural transplantation using pluripotent neuroepithelial cells: The subject invention pertains to a novel method of correction of behavioral and/or psychological deficits made possible by the intracerebral transplantation of pluripotent neuroepithelial cells. Cells, cell lines, pharmaceutical preparations, medicaments, methods for the production and maintenance of the cell lines for use in the method of the invention are...

20060051324 - Pharmaceutical composition for inducing an immune response in a human or animal: The present invention relates to a pharmaceutical composition for inducing an immune response in a human or animal, comprising dendritic cells loaded with at least five cancer/testis antigen and no lineage specific differentiation antigens or substantially no lineage specific differentiation antigens provided from at least one cancer cell line, as...

20060051327 - Use of synovium and omentum for tissue engineering: A method for treating a patient to repair or regenerate damaged tissues or organs in which synovium from a joint or omentum from the abdomen are harvested to provide explants, optionally separating cells from the synovium or omentum explants for culture or tissue specification, and introducting the explants or separated...

20060051336 - Bacteriolytic complex, method of its production, and strain for realization of the method: The inventions relate to the field of medicine, veterinary and biotechnology and may be used for production of a drug for medical and veterinary purposes. A bacteriolytic complex, produced by the bacterium Lysobacter sp. XL1, has been proposed, which contains bacteriolytic enzymes (muramidase, muramoylalanineamidase, endopeptidase, a bacteriolytic enzyme with a...

20060051337 - Escapin, a broadly antimicrobial compound from ink of the sea hare aplysia californica, and uses thereof: The present invention provides an isolated polypeptide (escapin), and fragments thereof, from the sea hare Aplysia californica that have antimicrobial action directed against fungi, yeast, bacteria, and cyanobacteria. Further, the present invention provides an isolated nucleic acid, and fragments thereof, that encode the polypeptide and fragments thereof. Also provided are...

20060051338 - Inhibition of mitogen-activated protein kinases in cardiovascular disease: The present invention relates to methods for inhibiting subacute thrombosis and/or intimal hyperplasia following an interventional vascular procedure by contacting a blood vessel or a synthetic material with a mitogen-activated protein kinase (MAPK) pathway inhibitor. The present invention further relates to vascular devices comprising a MAPK pathway inhibitor....

20060051339 - Composition for treatment of oily skin and acne prevention and methods of making and using same: Compositions and methods for the prevention and treatment of oily skin and the prevention and treatment of open comedos and acne using the enzyme lipase and an acceptable carrier are disclosed....

20060051340 - Hemostatic materials: A safe and effective hemostatic material is provided. A hemostatic material comprising as an effective ingredient thrombin and fibrinogen characterized in that a bioabsorbable synthetic nonwoven fabric is used as a supporting material. The use of the hemostatic material of the present invention allows for quick and thorough hemostasis for...

20060051341 - Methods for treating a buttock deformity: Methods for treating a buttock deformity or for preventing development of a buttock deformity by local administration of a Clostridial toxin, such as a botulinum neurotoxin, to a buttock deformity or to the vicinity of a buttock deformity....

20060051342 - Carrier having immobilized antigens or antibodies and method of manufacturing thereof: Carrier and method of its manufacture having immobilized antigens or antibodies, including a carrier having a surface, in which at least the surface of the carrier is formed of a calcium phosphate based compound; antiligands provided on and surrounding the surface of the carrier; a blocking layer formed of a...

20060051344 - Antibody and utilization of the same: The present invention relates to antibodies specifically reacting with partial peptides in the C-terminal region of polypeptides having amino acid sequences represented by SEQ ID NOS: 1 through 8 or derivatives thereof, a method of quantifying urotensin II using the antibodies, and pharmaceutical compositions comprising the antibodies (e.g., for central...

20060051351 - Erbb4 receptor-specific neuregulin related ligands and uses therefor: The invention concerns a novel neuregulin related ligand (NRG3) including fragments and variants thereof, as new members of the neuregulin family of compounds. The invention also concerns methods and means for producing NRG3. The native polypeptides of the invention are characterized by containing an extracellular domain including an EGF-like domain;...

20060051346 - Humanized anti-cd4 antibody with immunosuppressive properties: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions....

20060051349 - Immunotherapy of autoimmune disorders using antibodies which target b-cells: Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies....

20060051345 - Method for treating multiple sclerosis: Methods for treating multiple sclerosis (MS) with a CD20 antibody using special dosing regimens and protocols are described. Articles of manufacture for use in such methods are also described....

20060051348 - Method of producing a plurality of isolated antibodies to a plurality of cognate antigens: The present invention relates to a method for producing high affinity antibodies that are antigen-specific. The method involves binding a plurality of antibody-producing B-cells from a mammal to a plurality of cognate antigens; sorting the bound antibody-producing B-cell and cognate antigen; amplifying nucleic acid sequences encoding each antibody, or fragment...

20060051350 - Methods and means to suppress symptoms of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (gitr or tnfrsf18): The invention relates to the field of immunology, more in particular to the field of immune therapy, even more particularly to a method for regulating tolerance to an allergen in a subject and even more specifically, to methods which involve regulation of a glucocorticoid-induced tumor necrosis factor receptor (GITR). Provided...

20060051343 - Preventives remedies for bone and joint diseases: A compound or its salt that inhibits the activity of a protein having an amino acid sequence which is the same or substantially the same amino acid sequence represented by SEQ ID NO: 1, an antibody to the above protein, an antisense nucleotide having a base sequence which is complementary...

20060051347 - Process for concentration of antibodies and therapeutic products thereof: The present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C. The disclosure also includes a process for preparing highly concentrated antibody compositions, and highly concentrated antibody products....

20060051352 - Cea binding agents and compositions to reverse cea-mediated tumorigenic effects on human cancer cells, restore sensitivity to drug induced apoptosis and uses thereof: The present invention relates to differentiation, apoptosis and tumorigenicity. The present invention more particularly relates to compositions comprising ligands which target CEA such that the adhesion, differentiation-Inhibitory and apoptosis-resistance activities (tumorigenic effects) of Ig superfamily member, CEA, can be reduced or blocked. More particularly, the present invention relates to CEA-binding...

20060051353 - Methods and compositions to evaluate antibody treatment response: The present invention relates to methods and compositions to evaluate or assess the response of a subject to particular therapeutic treatment. More particularly, the invention provides methods to determine the response of subjects, or to adapt the treatment protocol of subjects treated with therapeutic antibodies. The invention is based on...

20060051354 - Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof: The present invention relates to an anti-cancer vaccine composition comprising an antigen in association with an effective amount of at least one immunomodulator chemotherapeutic adjuvant eliciting an immune response in a patient and a pharmaceutically acceptable carrier. It also relates to method of preventing tumor growth and reducing tumor growth...

20060051356 - Clostridial toxin derivatives able to modify peripheral sensory afferent functions: This invention describes a novel agent for the targeted control of a mammalian cell activity, in particular the agent is used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the treatment of a variety of disorders. An agent...

20060051355 - Methods and means for the treatment of immune-related diseases: The present invention provides novel means and methods for treating unwanted side effects in transplantations, such as GVHD and allograft rejection. The invention provides immunotoxins comprising an antibody and a toxic substance, whereby cocktails of such conjugates are directed to different targets associated with one population of cells, wherein one...

20060051358 - Immune response assessment method: The present invention includes compositions and methods for identifying T-cell epitopes independent of the subject's HLS type by simultaneously analyzing the culture for multiple parameters of immune reactivity to identify at least one epitope wherein the epitopes that elicit immune reactivity of interest in the subset are identified as targeting...

20060051357 - Tolerance induction with help of a combination of a lfa-1 inhibitor and a costimulation inhibitor and or a mtor inhibitor: A method for inducing or modulating T or B cells tolerance to donor cells, tissue or organ in a recipient comprising administering to the recipient a LFA-1 inhibitor in combination with a costimulation inhibitor and/or a mTOR inhibitor....

20060051359 - Recombinant immunotoxin and use in treating tumors: Immunotoxins are disclosed that include a toxin, a variable region of a heavy chain of a monoclonal antibody that binds the antigen specifically bound by monoclonal antibody 8H9, and a variable region of a light chain of the monoclonal antibody that binds the antigen specifically bound by monoclonal antibody 8H9...

20060051360 - Tat as an immunogen: Non-denatured, recombinant human immunodeficiency virus (HIV) Tat that is free of bacterial RNA and endotoxin is employed in an anti-HIV vaccine. A process of producing the recombinant Tat protein includes steps for removing bacterial RNA from the recombinant Tat and for removing endotoxin from the recombinant Tat protein. A Tat-adsorbed...

20060051362 - Antigens for actinobacillus pleuropneumoniae and methods thereof: The present invention is related to a DNA sequence of outer membrane proteins of Actinobacillus pleuropneumoniae expressed in a subject suffering from pleuropneumonia, the sequence coding for the receptor for the uptake of ferric hydroxamate FhuA as set forth in SEQ ID NO: 1 in Actinobacillus pleuropneumoniae, or any functional...

20060051364 - Lutzomyia longipalpis polypeptides and methods of use: Substantially purified salivary Lu. longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the Lu. longipalpis polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing...

20060051363 - Protein inducing cell death of helicobacter pylori: The present invention revealed that the apoptosis-inducing protein of Helicobacter pylon is a protein complex composed by association of two kinds of proteins, which comprise a part of the amino acid sequence encoded by γ-glutamyl transferase gene (HP1118). The present invention is said protein and a vaccine comprising said protein....

20060051361 - Vaccine against streptococcus pneumoniae: The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to vaccines comprising a pneumococcal polysaccharide antigen, typically a pneumococcal polysaccharide conjugate antigen from Streptococcus pneumoniae selected from the group consisting of PhtA, PhtD, PhtB, PhtE, SpsA, LytB, LytC, LytA, Sp125, Sp101,...

20060051365 - Immunogenic composition: The present invention provides an immunogenic composition comprising a fusion protein and a saponin adjuvant. The fusion protein comprises a heterologous hydrophobic peptide that is fused to the N-terminus and/or to the C-terminus of a core polypeptide. The core polypeptide comprises at least one protective epitope. The saponin adjuvant in...

20060051367 - Antigenic polypeptide sequences of factor viii, and fragments and/or epitopes of these sequences: The present invention is related to the antigenic polypeptide sequence of Factor VIII....

20060051366 - Use of soluble cd26 as inhibitor of angiogenesis and inflammation: The present invention relates to soluble CD26 or a biologically active variant of the soluble CD26 that effectively inhibits angiogenesis and inflammation in a mammalian subject, pharmaceutical compositions comprising the soluble CD26 and the use of soluble CD26 in methods of treatment....

20060051369 - Adar1 antiviral pathway: Methods for enhancing the production of viral vaccines in cell culture are described, as are the cell cultures. These methods rely on the suppression of the levels of ADAR1 in interferon-deficient cells. The methods comprise (a) infecting a cell culture with a donor virus, wherein said cell culture is an...

20060051368 - Herpes simplex virus mutations: The present invention relates to compositions and methods related to mutant herpes simplex virus nucleic acid and proteins that find use in analyzing, diagnosing, and regulating viral infection....

20060051370 - Microorganisms for therapy: Therapeutic methods and microorganisms therefor are provided. The microorganisms are designed to accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so that they exhibit relatively low toxicity to host organisms. The microorganisms also...

20060051371 - Live attenuated vaccine against porcine pleuropneumonia: The present invention provides a method for obtaining an immunogenic, non-haemolytic strain of Actinobacillus pleuropneumoniae which is modified, at least in a segment of the apxIA gene and optionally in a segment of the apxIIA gene that encodes a transmembrane domain of the Apx haemolytic and cytolytic exotoxins. It comprises...

20060051372 - Antigenic compounds: The present invention relates to novel antigenic compositions suitable for parenteral and mucosal administration, comprising an antigen within an aqueous medium and a carbohydrate, wherein the carbohydrate is in the form of a derivative which exhibits acidic moieties, preferably in the form of its carboxylic acid derivative. The antigenic compositions...

20060051374 - Compositions and methods for mucosal vaccination: The present invention provides pharmaceutical combinations that include an IRM compound formulated for mucosal administration and an antigen formulated for mucosal administration. Additionally, the invention provides methods for immunizing a subject. Generally, the methods include administering an antigen to a mucosal surface of the subject in an amount effective, in...

20060051373 - Particle-bound human immunodeficiency virus envelope glycoproteins and related compositions and methods: This invention provides a first composition comprising a pharmaceutically acceptable particle and a stable HIV-1 pre-fusion envelope glycoprotein trimeric complex operably affixed thereto. This invention further provides a second composition comprising (a) a pharmaceutically acceptable particle, (b) an antigen, and (c) an agent which is operably affixed to the particle...

20060051375 - Rabbit skin comprising biological active substances and its use: A rabbit skin containing biologically active substances is obtained by the process including vaccinating rabbit skin tissues with vaccinia virus, feeding a rabbit vaccinated with vaccinia virus, killing the rabbit when its skin tissues are sufficiently inflamed, and skinning the rabbit. The rabbit skin of the present invention can be...

20060051376 - Remedy for fibromyalgia: A therapeutic agent for fibromyalgia containing an extract from inflamed tissue inoculated with vaccinia virus as an active ingredient, use of the extract from inflamed tissue inoculated with vaccinia virus as the active ingredient for producing a medicinal composition for treating fibromyalgia, and a method of treating fibromyalgia which comprises...

20060051377 - Stretch mark treatment: Methods for treating stretch marks by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a stretch mark....

20060051378 - Mucosal vaccines with chitosan adjuvant and meningococcal antigens: The invention provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N. meningitidis, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and/or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery....

20060051379 - Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines....

20060051380 - Methods and compositions for the targeting of a systemic immune response to specific organs or tissues: The invention provides methods and compositions for targeting a separately generated immune response to a specific organ or tissue, e.g. one affected by cancer, using one or more agents with a tropism for the organ or tissue or that can be specifically localized to the desired organ or tissue. For...

20060051381 - Cytokine antagonists for neurological and neuropsychiatric disorders: Methods for treating neurological or neuropsychiatric diseases or disorders in humans by administering to the human a therapeutically effective dose of specific biologics are presented. The biologics of consideration include antagonists of tumor necrosis factor or of interleukin-1. The administration of these biologics is performed by specific methods, most, but...

20060051382 - Compositions for body hairs and/or head hair: Compositions which can be applied to body hairs or head hair, comprising an aqueous suspension of magnetic latex microspheres and of colloidal nanoparticles of magnetic pigment....

20060051383 - Preparation, in particular cosmetic preparation, and the production and use thereof: A preparation, in particular a cosmetic preparation, in the form of a workable paste which is present in the form of a W/O emulsion and which is suitable for cosmetic uses, in particular in the area of decorative cosmetics for coloring and improving the skin, the lips and the eyelids....

20060051384 - Antiseptic compositions and methods of use: Antimicrobial compositions, especially those useful when applied topically to tissue, such as mucosal tissues (i.e., mucous membranes), that include an antimicrobial selected from the group consisting of peroxides, C6-C14 alkyl carboxylic acids, C6-C14 alkyl carboxylate ester carboxylic acids, C8-C22 mono- or polyunsaturated carboxylic acids, and antimicrobial natural oils. The compositions...

20060051385 - Cationic antiseptic compositions and methods of use: Antimicrobial compositions, especially those useful when applied topically, particularly to mucosal tissues (i.e., mucous membranes), including a cationic antiseptic such as biguanides and bisbiguanides such as chlorhexidine and its various salts including but not limited to the digluconate, diacetate, dimethosulfate, and dilactate salts; polymeric quaternary ammonium compounds such as polyhexamethylenebiguanide;...

20060051386 - Combinations of active ingredients, which exhibit insecticidal and acaricidal properties: t

20060051387 - Sterilant system: A two-part sterilant system comprises a first part comprising a first reagent in a carrier medium and a second part which is miscible with the first part and which comprises a second reagent in a carrier medium. The first reagent and the second reagent will react when mixed to provide...

20060051388 - Lipid carriers: There is disclosed a method of controlling pests which comprises exposing a surface of the pest to a particulate composition containing particles of an initially unmagnetized material, which is capable of becoming magnetically polarized when subjected to an electric or magnetic field, the said particles being associated with at least...

20060051389 - Sustained release polymer-based water insoluble beads: The invention provides a sustained release, polymer-based, water insoluble bead, comprising a polymeric matrix containing a plurality of emulsion droplets, said droplets being formed from at least one surface active molecule, at lease one volatile hydrophobic component and water, wherein said volatile component is released from said water insoluble bead...

20060051391 - Device for the controlled administration of substances to be inserted in a body cavity: Device for the controlled administration of substances to be inserted in a body cavity, characterized by: an anchoring medium allowing for a firm anchorage of the device in said body cavity; at least one substance support medium for the release of at least one substance into the body cavity following...

20060051390 - Medical devices having self-forming rate-controlling barrier for drug release: Therapeutic-agent-releasing medical devices are provided herein, which contain a rate controlling release region that includes a biodisintegrable agent and a biostable low glass transition temperature polymer. Upon contact (e.g., implantation or insertion) of the medical device with a subject, at least the surface of the release region becomes depleted of...

20060051394 - Biodegradable polyurethane and polyurethane ureas: This invention relates to biocompatible, biodegradable thermoplastic polyurethane or polyurethane/ureas comprising isocyanate, polyol and a conventional chain extender and/or a chain extender having a hydrolysable linking group and their use in tissue engineering and repair applications, particularly as stents and stent coating....

20060051396 - Biofunctional coatings: The present invention provides compositions and methods for an improved coating for medical devices. The coating is an interfacial biomaterial (“IFBM”) which comprises at least one binding module that binds to the surface of a device (“surface-binding module”) and at least one binding module that performs another function (“affector module”)...

20060051395 - Ifbms to promote the specific attachment of target analytes to the surface of orthopedic implants: The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that...

20060051397 - Metallic structures incorporating bioactive materials and methods for creating the same: Disclosed herein are methods to create medical devices and medical devices including bioactive composite structures. The methods include using electroless and electrophoretic deposition and codeposition methods for providing implantable medical devices coated with bioactive composite structures. In one use, the implantable medical devices of the present invention include stents with...

20060051393 - Method of manufacturing drug-eluting medical device: Methods for manufacturing medical devices comprising a polymeric material capable of releasing a therapeutic agent upon contact with bodily tissue or fluid are described. The method includes generating polymeric material having a matrix into or onto which a therapeutic agent is disposed and having pores. The method further includes disposing...

20060051392 - Porous coatings for drug release from medical devices: Extravascular implantable medical devices are described. The devices include a polymeric layer comprising a polymeric matrix and pores. Therapeutic agent is loaded in the matrix, in the pores, or in the matrix and the pores. The devices include a structural surface layer. Additional therapeutic agent may be loaded in or...

20060051398 - Method of preventing post-operative surgical adhesion: A method for preventing adhesion using a co-polyester comprising the reaction product of a polycondensation polyester and at least one lactone, wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and ethylene glycol; and the co-polyester comprises about 40 to 50% by weight of...

20060051399 - Remedies for liver diseases, hyperlipemia and diabetes: Drugs and foods for preventing and/or treating liver diseases, hyperlipemia and/or diabetes containing a peptide which is composed of L-amino acids constituting natural proteins, has an L-glutamine content of from 15 to 60% by mass and has an average molecular weight of from 200 to 100,000; and foods containing this...

20060051400 - Steam stable enzyme compositions: Enzyme compositions that are steam stable and methods for producing the same are described. In one embodiment, the enzyme composition breaks down in the presence of water, thereby releasing the enzyme for catalytic function....

20060051401 - Controlled nanofiber seeding: The present invention includes compositions and methods for the controlled formation of nano and micropolymers in a single-step that includes a structural substrate, an oxidatively reactive monomer and an oxidant to form a polymer that takes the morphology of the structural substrate....

20060051402 - Splinting orthopedic and rehabilitative product: The invention provides a splinting orthopedic or a rehabilitative product that has an increased resistance to odor and/or microbial growth. More particularly, the invention provides for a moldable splinting orthopedic or a rehabilitative product comprising an antibiotic agent and low temperature thermoplastic polymer....

20060051403 - Microprojection array with improved skin adhesion and compliance: A transdermal delivery system having a microprojection array with one or more voids configured to allow an adhesive backing to attach to a user's skin and, hence, improve retention of the system thereto. Radial voids can be configured to enhance compliance of the array to conform more readily to non-flat...

20060051404 - Microstructure roller system: A microstructure for transferring a substance through the surface of the skin, comprising a substrate having a first and a second side and at least one microstructure projecting from the second side of the substrate. The micrstructure has at least one hollow. The hollow is isolated from the fluid connection...

20060051405 - Compositions for the delivery of therapeutic agents and uses thereof: The present invention provides drug delivery vehicles comprising polytheylyene-lipid conjugates (PEG-lipid), wherein the circulation lifetime and biodistribution of the drug delivery vehicles are regulated by the PEG-lipid. More particularly, the present invention provides liposomes, SNALP and SPLP comprising such PEG-lipid conjugates, and methods of using such compositions to selectively target...

20060051406 - Formulation of insoluble small molecule therapeutics in lipid-based carriers: The present invention provides formulations containing at least one unsaturated amphiphilic lipid and an amphipathic or hydrophobic drug and methods of making these formulations. In particular, the present invention provides formulations of least one unsaturated phospholipid and an amphipathic or hydrophobic pyrimidine drug, methods of making these formulations and the...

20060051407 - Method of treating ischemia-reperfusion injury: The present invention relates to methods and compositions designed for the prevention, reduction, treatment or management of ischemia-reperfusion injury. The methods of the invention comprise the administration of an effective amount of a therapeutic formulation containing one or more active compounds in a formulation which specifically decreases or inhibits the...

20060051408 - Microcapsules for stabilization of cosmetic, pharmaceutical or food products: Microcapsules for stabilisation of cosmetic, pharmaceutical or food products, of a size smaller than 500 μm, comprising a nucleus of an adsorbent material—natural or modified polysaccharide insoluble in water, or an adsorbent inorganic material—in which are contained the active ingredients and is coated by a polymeric material—natural, modified natural or...

20060051409 - Bezonatate liquid hard capsule dosage form: A pharmaceutical dosage includes a hard capsule, benzonatate and a sealer ring. The hard capsule has a bottom half and a top half that covers the bottom half. The benzonatate is in liquid form and is placed in the bottom half of the hard capsule. The sealer ring seals the...

20060051411 - Antibacterial medicinal composition of enhanced oral absorptivity: An objective of the present invention is to provide a cefditoren pivoxil pharmaceutical preparation which can safely be administered to a patient and not only improves wettability of cefditoren pivoxil, but also further improves absorbability through the intestinal tracts by maintaining amorphous particles having a high oral absorbability in a...

20060051414 - Fast water-dispersible domperidone tablets: The present invention relates to fast water-dispersible tablets containing domperidone for oral administration. The formulations comprise domperidone or pharmaceutically acceptable salts thereof, about 60-80% of a “auxiliary” granulate (w/w), and about 10-30% of microcrystalline cellulose (w/w), expressed in relation to the total weight of the tablets, a sweetener, a flavouring...

20060051412 - Method for producing an immediately decomposing oral form of administration which releases active ingredients: The invention relates to a method for producing an oral form of administration which decomposes immediately and releases active ingredients in the mouth. According to said method, (a) an anionic pharmaceutical active ingredient is intensively mixed with (b) a copolymer consisting of radically polymerized C1-C4 esters of the acrylic acid...

20060051413 - Method of enhancing absorptions of transmucosal administration formulations: Disclosed is a method for enhancing absorption of a medicament that is suitable for administering transmucosally to a subject by providing an environment of the administration with a suitable pH. A medicament of propranolol suitably administered sublingually is provided. The medicament of propranolol can be used for treating cardiovascular diseases....

20060051415 - Method of enhancing absorptions of transmucosal administration formulations: Disclosed is a method for enhancing absorption of a medicament that is suitable for administering transmucosally to a subject by providing an environment of the administration with a suitable pH. A medicament of propranolol suitably administered sublingually is provided. The medicament of propranolol can be used for treating diseases related...

20060051410 - Pharmaceutical composition containing 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid: A highly stable pharmaceutical composition which comprises a mixture comprising a substance selected from the group consisting of 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid, salts thereof, and esters thereof, and croscarmellose sodium....

20060051417 - Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof: An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix, the matrix comprising at least two water swelling polymers, wherein one of the polymers is pregelatinized starch, and wherein another one of the polymers is an anionic polymer....

20060051416 - Modified release formulations of memantine oral dosage forms: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active...

20060051418 - Pharmaceutical formulations of potassium atp channel openers and uses thereof: Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel...

20060051419 - Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof: An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient....

20060051420 - Pharmaceutical tablets containing tibolone and a coating: The present invention relates to a stabilized pharmaceutical tablet comprising an amount of from 0.1 to 10% by weight of tibolone provided with a coating, such as a film coating, a sugar coating, a sugar film coating or a “wrap” coating. The invention further relates to the use of a...

20060051421 - Stable pharmaceutical formulations of benzimidazole compounds: Provided are stable pharmaceutical formulations of benzimidazole compounds, particularly esomeprazole magnesium, and processes for their preparation....

20060051422 - Stabilised solid drug dispersions in an organic carrier and a process for preparing the same: New solid drug dispersions are described in which the drug is present in amorphous form and massively dispersed (in bulk) inside the particles of an organic carrier selected from cross-linked polymers and/or a complexing agents. These dispersions are obtainable by mixing together the drug and the carrier and applying an...

20060051423 - Chitosan-based transport system: The invention relates to a chitosan-based transport system for overcoming the blood-brain barrier. This transport system can convey active agents or markers into the brain. The transport system contains at least one substance selected from the group consisting of chitin, chitosan, chitosan oligosaccharides, glucosamine, and derivatives thereof, and optionally one...

20060051424 - Compositions of oral gene therapy and methods of using same: The present invention provides nanoparticle compositions comprising a cationic biopolymer and at least one biologically active substance, pharmaceutical compositions comprising such nanoparticles and methods for the oral administration of biologically active molecules which are susceptible to degradation in the gastro-intestinal tract using nanoparticle. The present invention further provides compositions and...

20060051425 - Method of microencapsulation: The present invention provides methods for microencapsulation of active ingredients for topical application, whereby single-layer and multi-layer, preferably double-layer, microcapsules, are obtained. The microcapsules protect the active ingredients, maintain their original activity throught processing, formulation and storage, and enable controlled release of the active ingredient only upon application onto the...

20060051426 - Nanoparticles containing polymeric nucleic acid homologs pharmaceutical composition and articles of manufacture containing same and methods of use thereof: A nanoparticle capable of delivery of an encapsulated molecule into a living cell. The nanoparticle includes an encapsulation media and an isolated nucleic acid homolog sequence. The encapsulation media is primarily polymeric. The nanoparticles release the encapsulated molecule over an extended period of time. Further disclosed are pharmaceutical compositions and...

20060051427 - Compositions for repairing bone and methods for preparing and using such compositions: This invention relates to an improved method of preparing an implantable gel or paste for placement between injured bones or placement in bony voids to induce regeneration, and the compositions produced thereby. Specifically, mineral, ceramic, or processed bone particles are coated with a high molecular weight polymer capable of forming...

20060051428 - Aspartame and citrate flavored phosphate salt laxative: The present invention provides compositions, kits, and methods suitable for cleansing the colon before colonoscopy. The compositions include a phosphate salt and a flavorant that includes aspartame and a citrate. The kits include the previously mentioned compositions and also may include suitable containers, packaging, relief wipes, and instructions for use....

20060051429 - Pharmaceutical compositions and methods for managing skin conditions: This application relates to a stable pharmaceutical composition and methods for the cleaning of skin to facilitate the prevention, treatment, and management of skin conditions, such as seborrheic dermatitis, psoriasis, folliculitis, rosacea, perioral dermatitis, acne, impetigo and other inflammatory skin conditions, and the like, including a sufficient amount of an...

20060051431 - Methods of managing multi-tissue injuries: The invention provides methods of managing multi-tissue injuries under tissue regenerating conditions, the methods comprising contacting injured tissues with a silver ion based topical pharmaceutical composition and covering the injury with an occlusive dressing. Methods of the invention can restore flexibility, sensation, and appearance of damaged tissues....

20060051430 - Silver dihydrogen citrate compositions: Personal care and home care compositions are disclosed, which include silver dihydrogen citrate. The inventive compositions advantageously take the form of suspensions, pastes, liquids and gels. The inventive compositions also optionally comprise additional ingredients, and are therefore suitable for a wide variety of personal, home and industrial care purposes....

20060051432 - Topical medicament: New topical medicaments are provided. The medicaments comprise menthol and camphor, preferably provided as part of a base gel, supplemented with potassium and a source of oxygen. The most preferred base gel is sold under the name SOMBRA, while the most preferred source of oxygen is a chlorite (e.g., sodium...

20060051434 - Cleaning tool: An indoor cleaning tool having a dry fibrous base material is provided. An antigenicity-reducing composition that includes an antigenicity-reducing component, a lubricant, and a surfactant is applied to the fibrous base material. Preferably, the antigenicity-reducing component is an extract of an olea or a ligustrum plant extracted with water or...

20060051433 - Composition for accelerating secretion of estrogen and regenerating tissue cells of female sexual organs: The present invention relates to a composition for accelerating secretion of estrogen and regenerating tissue cells of female sexual organs, more particularly; to a composition for accelerating secretion of estrogen and regenerating tissue cells of female sexual organs in postmenopausal women comprising one or more of Platycodi Radix and Cynanchum...

20060051436 - Composition for controlling excessive calorie intake-induced disorder, food product for controlling excessive calorie intake-induced disorder, skin preparation for external use for controlling excessive calorie intake-induced disorder, and controlling age: A composition contains 0.1 to 10 g of dried Hercampuri extract obtained by extracting the essence of dried whole Hercampuri plant with 60 to 80% aqueous ethanol. It has a function of prevention or curative treatment of lifestyle-related disorders induced by accumulation of visceral fat resulting from excessive calorie intake....

20060051435 - Nutritional supplement for body fat reduction: The present invention is directed to compositions containing a conjugated linoleic acid derivative, a banaba extract and an extract of Phaseolis vulgaris and methods of treatment for weight loss....

20060051438 - Herbal medicaments for the treatment of neurocerebrovascular disorders: The present invention relates to A composition obtained from the lipid soluble extract of rhizomes and leaves of Curcuma species of Zingiberaceae family, useful for the treatment of neurocerebrovascular disorders, said composition comprising fraction A consisting of ar-turmerone of formula 1, and turmerone of formula 2, and/or along with fraction...

20060051437 - Process for preparing a ginger fraction and the use thereof for inhibiting human cyp enzymes: The present invention relates to a process for preparing a ginger fraction, the fraction prepared by this process and the use thereof on its own or combined with drugs for inhibiting human cytochrome P450 (CYP) enzymes (particularly cytochrome P450 3A4, CYP3A4) for positively influencing the oral bioavailability and pharmacokinetics of...

20060051439 - Antioxidant, skin preparation for external use, cosmetic and food: The invention relates to antioxidants that make effective use of acerola seeds, which have conventionally been discarded, that have high safety and excellent antioxidative effect in skin preparations for external use, cosmetics, and food, and that contain acerola seed extract as an active component. The invention also relates to skin...

20060051440 - Factors that bind intestinal toxins: Methods for neutralizing bacterial toxins such as Shiga toxins and cholera toxins are disclosed. In a particular embodiment, a method is provided for treating a subject suffering from an infection caused by an Stx-producing organism by administering a therapeutically effective amount of a hop bract tannin obtained from Humulus lupulus....

20060045845 - Neux- a new composition of matter: This patent application is for a new composition of matter called “neuX”. It consists of two or more fundamental particles, called neutrons, that have no electric charge and are bound together by the so-called “strong forces”. Units of neuX, which may consist of any number of neutrons, are for use...

20060045846 - Reagents and methods for labeling terminal olefins: wherein RA and RB are independently hydrogen, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aryl or heteroaryl moiety, with the proviso that RA and RB are not each hydrogen, or RA and RB taken together with the carbon atom to which they are attached form an alicyclic or heterocyclic moiety; and...

20060045847 - Method for determination of anabolic activity: Novel methods for determining the anabolic activity of a compound in muscle using microarrays to compare the in vivo changes of the genomic profile of mammalian muscle induced by a tested compound versus the corresponding changes induced by a known anabolic steroid. For example, in vivo changes of the genomic...

20060045848 - Conscience-enhancing malice-weakening gas: This invention is a mixture of neuroactive substances in the form of gases, liquid aerosols, and/or solid aerosols, which act synergistically to increase the ratio of strength between the desire to do right, called conscience, and the desire to do wrong, called malice. Neurochemically, that corresponds to increasing the ratio...

20060045849 - Method of customizing the fragrance of nasal medications: Disclosed is a process for improving the scent of nasal medication comprising the steps of presenting a person with a fragrance choice comprised of a plurality of fragrance selections, receiving from the person a selection of a fragrance from said fragrance choice, thereby producing a selected fragrance, and adding to...

20060045850 - Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids: Aqueous, anti-inflammatory steroid compositions in solution form suitable for nasal administration and having a reduced stinging sensation are provided as well as a method for treating inflammation of the nasal mucosa by intranasal administration of anti-inflammatory steroid compositions. These solution compositions may result in enhanced nasal bio-availability. The anti-inflammatory steroid...

20060045851 - Oral care composition comprising essential oils: An essential oil composition comprising at least two essential oil from Group A which includes mint and spice essential oils and at least one essential oil from Group B which includes citrus essential oils. This essential oil composition can effectively kill and remove oral microbials which are correlated to the...

20060045852 - Materials and methods for tooth surface preparation for dental bonding: Surface conditioner compositions and methods for hemostatic control are provided for preparing tooth surfaces for bonding with dental restorations such as crowns or veneers. One embodiment of the composition includes an etchant and at least one hemostatic agent. A second embodiment of the composition includes an etchant, a hemostatic agent...

20060045853 - Cross-beta structure comprising amyloid-binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity: The invention relates to the field of biochemistry, molecular biology, structural biology and medicine. More in particular, the invention relates to cross-β structures and the biological role of these cross-β structures. In one embodiment, the invention discloses a method for modulating extracellular protein degradation and/or protein clearance comprising modulating cross-β(beta)...

20060045854 - Oral care composition with cross-linked polymer peroxide: Oral care compositions comprising: (a) a peroxide complex comprising a peroxide component and an N-vinyl heterocyclic polymer (e.g., poly-N-vinyl polylactam, or poly-N-vinyl-polyimide); (b) a whitening agent (e.g., hydrogen peroxide); and (c) an orally acceptable carrier. In one embodiment, the carrier comprises a film forming material. Methods are also provided for...

20060045855 - Oral composition for reducing plaque and microbial infections and whitening teeth: A dental mouthwash product, and method of use, comprising a water-soluble chlorite compound in a first solution, a hydrogen peroxide and a physiologically acceptable readily water-soluble oxidizing agent in a second solution, or optionally the oxidizing agent separate from the second solution as a powder, tablet, gel capsule, or liquid,...

20060045858 - Composition and method for reducing harmful effects of ultraviolet radiation impinging on the skin: A composition is provided that is suitable for topical administration for the treatment of skin to reduce the harmful effects of ultraviolet radiation impinging on the skin, the composition comprising acetylsalicylic acid and sodium bicarbonate. Also provided is a method for treating skin to reduce the harmful effects of ultraviolet...

20060045856 - Composition containing a dihydroxyacetone precursor: The invention relates to a cosmetic or dermatological composition containing at least one precursor of a substance whose active form is sought for its cosmetic activity. One of the applications of the invention relates to compositions capable of rapidly imparting to the skin a color similar to that obtained on...

20060045859 - S-triazine sunscreens bearing hindered para-aminobenzalmalonate/para-aminobenzalmalonamide and aminobenzoate/aminobenzamide substituents: e

20060045857 - Sunless tanning composition and methods for using: A sunless tanning composition is provided according to the invention. The sunless tanning composition includes a polymer component, a tanning active component, water, and the composition is provided as an emulsion and has a viscosity of less than about 25 cSt. A method for using a sunless tanning composition is...

20060045860 - Zinc zeolite based deodorants and deodorizers: This invention relates to Zinc Zeolite based deodorant or deodorizing compositions useful for human or animal body or hair deodorizing solution, deodorizing powder, deodorizing gel, deodorizing spray, deodorizing stick, deodorizing roll-on, deodorizing paste, deodorizing cream, deodorizing lotion, deodorizing aerosol; human or animal deodorizing dentifrice, or oral cavity deodorizing toothpaste, deodorizing...

20060045862 - Hair cosmetic composition: i

20060045861 - Reduced odor in low molecular weight cationic polygalactomannan: A reduced odor composition is composed of at least one cationic polygalactomannan or a derivative of cationic polygalactomannan having a weight average molecular weight (Mw) having a lower limit of 5,000 and an upper limit of 200,000, a light transmittance in a 10% aqueous solution of greater than 80% at...

20060045864 - Preventing marine biofouling by inhibiting adhesive release from barnacles: Use of relatively harmless pharmacological substances, such as dopamine antagonists, that prevent the release of adhesive or in other way prevent the attachment of the barnacle larva. Dopamine antagonists are mixed with a paint polymer and applied on a ship hull, or any other man-made solid surface in the marine...

20060045863 - Self-polishing antifouling paint: A self-polishing antifouling paint comprising a binder and a biologically active substance, wherein said biologically active substance is chosen to be decomposable in the presence of water and to consume oxygen in its process of decomposition so as to generate an oxygen-lean aqueous environment in the water-exposed paint outer layer....

20060045865 - Controlled regional oral delivery: A composite formulation has been developed for selective, high efficacy delivery to specific regions of the mouth and gastrointestinal tract. The formulation is typically in the form of a tablet or capsule, which may include microparticles or beads. The formulation uses bioadhesive and controlled release elements to direct release to...

20060045866 - Novel high purity and high molecular weight mpeg alcohol compositions: The invention is directed toward novel high molecular weight and high purity mPEG alcohol compositions as well as a process for obtaining said compositions by removing PEG diols from the mPEG alcohol after polymerization is complete....

20060045867 - Regeneration method for treating heart diseases and vascular system diseases using medicament: A regeneration method using a medicament against heart diseases and vascular system diseases, which comprises administering a polypeptide having granulocyte colony-stimulating factor activity under bone marrow suppressed conditions....

20060045868 - Absorption enhancers for drug administration: A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via...

20060045869 - Absorption enhancers for drug administration: A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via...

20060045873 - Induction of methylation of cpg sequences by dsrnas in mammalian cells: The present inventors found that in human cells, synthetic small interfering RNAs (siRNAs) targeted to a region containing the CpG islands on gene promoters will specifically induce the methylation of CpG sequences within the target region or adjacent regions. Methylation of the promoters results in suppression at a transcriptional level...

20060045871 - Antioxidant activity from methanotrophic biomass: A natural antioxidant, Coenzyme Q8, is produced in methanotropic bacteria. However, current processing techniques for methanotrophic biomass leads to the oxidation of the natural antioxidant. The present methods process the dried methanotrophic biomass so that more of the reduced form (i.e. the form having antioxidant activity) is retained. The increased...

20060045870 - Lactic acid bacteria inhibiting halitosis: The present invention relates to novel bacteria inhibiting halitosis or oral malodor. In particular, the present invention relates to novel lactic acid bacteria belonging to the genus Weissella, which can inhibit the proliferation of anaerobic bacteria producing volatile sulfur compounds by interacting with them and generating hydrogen peroxide under aerobic...

20060045872 - Use of adipose tissue-derived stromal stem cells in treating fistula: Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae....

20060045874 - Aminoglycoside treatment for lysosomal storage diseases: The present invention provides a method of treating lysosomal storage diseases such as Hurler syndrome and Batten disease in individuals in need of such treatment, comprising the step of administering to said individuals a therapeutically effective dose of an aminoglycoside. In addition, this method may further comprise treating the individual...

20060045875 - Method of use of crotoxin as an anti-retroviral agent: The present invention provides a composition of matter and a method of using the composition for treating and preventing of retroviral infections of mammalian cells. It includes identification of Crotalus beta-neurotoxins as capable of preventing HIV infection and replication in that cell and a retroviral composition which can be administered...

20060045879 - Antibodies which are directed against the marburg i polymorphism of factor vii-activating protease (fsap), and their preparation and use: The invention relates to antibodies which are directed against the FSAP Marburg I variant and to their preparation and use, in particular in therapy and diagnosis. The antibodies are characterized by the fact that they bind specifically to the FSAP MR I variant but not to the FSAP wild-type protein...

20060045876 - Fusion proteins of humanized g250 specific antibodies and uses thereof: Chimeric antibodies, as well as fusion proteins which comprise chimeric antibodies, are disclosed. The antibodies bind to GM-CSF, CD-30, and G250 antigen. The fusion proteins include biologically active portions of tumor necrosis factor, or full length tumor necrosis factor. Expression vectors adapted for production of the antibodies, as well as...

20060045877 - Immunoconjugates targeting syndecan-1 expressing cells and use thereof: Immunoconjugates comprising a targeting agent selectively targeting cell-surface expressed syndecan-1 and at least one effector molecule as well as in vitro and in vivo methods of using those immunocomjugates are disclosed. The effector molecule may have, in its native form, high non-selective cytotoxicity, but substantially no non-selective cytotoxicity when part...

20060045878 - Pancreas-derived plasminogen activator inhibitor: The present invention relates to a novel member of the plasminogen activator inhibitor protein family. In particular, isolated nucleic acid molecules are provided encoding the pancreas-derived plasminogen activator inhibitor protein. Pancreas-derived plasminogen activator inhibitor polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same....

20060045880 - Methods for modulating angiogenesis and apoptosis with apelin compositions: Novel methods of inhibiting angiogenesis or tumorigenesis or promoting apoptosis with compositions that inhibit the apelin/APJ signaling pathway are provided. Also provided are methods of promoting angiogenesis or inhibiting apoptosis with compositions comprising an apelin polypeptide or small molecule agonist. The present invention further provides methods for identifying therapeutic agents...

20060045881 - Anti-cancer vaccines: The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as vaccines for treating or preventing cancers in a patient. In specific aspects, neutrophil elastase peptides other than PR1, cyclin E1 peptides, cyclin D peptides, or cyclin E2 peptides are provided. Such peptides can be used to elicit...

20060045882 - Developing oral tolerance for airborne allergens: A method is disclosed for developing desensitization to airborne allergens in persons suffering from allergic reactions to such substances. This desensitization is developed by orally administering airborne allergens collected from the environment which leads to allergy symptoms in the user. The illustrative embodiments collect airborne allergens in water by passing...

20060045883 - Anti-cancer vaccines: The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as vaccines for treating or preventing cancers in a patient. In specific aspects, there is proteinase 3 peptides are provided. Such peptides can be used to elicit specific CTLs that preferentially attack myeloid leukemia based on overexpression of...

20060045884 - Vaccines for autoimmune and infectious disease: The present invention provides HLA-restricted antigens as vaccines for treating or preventing autoimmune diseases or conditions, translpant rejection or vasculitis in a patient. In particular aspects, there is provided Pr3, a myeloid tissue-restricted protein and a HLA-A2.1-restricted self-peptide, PR1, derived from Pr3, which can be used to elicit PR1-specific CTLs....

20060045886 - Hiv immunostimulatory compositions: The present invention provides an IRM-HIV composition that includes an IRM portion paired with an HIV antigenic portion....

20060045885 - Method of eliciting an immune response against hiv: The present invention provides methods of eliciting an immune response against HIV. Generally, the method includes administering to a subject an effective amount of an IRM-HIV composition that includes an IRM portion paired with an HIV antigenic portion....

20060045887 - Mushroom extracts having anticancer activity: The invention relates to compositions comprising a mycelium extract from at least one higher Basidiomycetes medicinal mushroom selected from the group consisting of Ganoderma adspersum, Hypsizygus ulmarium, Kuehneromyces mutabilis, Omphalotus olearius, Panus conchatus, Piptoporus betulinus, Pleurotus eryngii, and Trametes zonata, said composition having selective antiproliferative activity on the human chronic...

20060045888 - Antigen library immunization: This invention is directed to antigen library immunization, which provides methods for obtaining antigens having improved properties for therapeutic and other uses. The methods are useful for obtaining improved antigens that can induce an immune response against pathogens, cancer, and other conditions, as well as antigens that are effective in...

20060045889 - Novel recombinant sabin type 1 poliovirus vector and vaccine against poliovirus: The present invention relates to a novel recombinant Sabin type 1 poliovirus vector for the immunogenicity of neutralizing antibody against polioviral infection, which comprises: (a) a genomic nucleotide sequence of a parent Sabin type 1 poliovirus; (b) a nucleotide sequence encoding an additional polioviral cleavage site; and (c) a nucleotide...

20060045891 - Density-matched suspension vehicles and pharmaceutical suspensions: Density-matching is used to provide suspending vehicles, pharmaceutical suspensions, dosage forms, and kits as well as methods of making and using the vehicles, suspensions, and dosage forms. Pharmaceutical suspensions comprising a pharmaceutically active agent having an active agent density, ρA, and a suspending vehicle having a suspending vehicle density, ρSV;...

20060045890 - Topical skin care compositions: A novel combination of silicon resin, amorphous silica and low oil absorbing spherical powder is described which when added to topical skin care compositions containing high concentrations of active agents, improves their aesthetic feel and ease of application....

20060045894 - Compound for neck skin firming: A topical compound for reducing sagging or wrinkles in the neck area of human skin. The compound includes safe and effective amounts of a mild topical astringent (such as Camphor) for skin tightening, a topical antispasmodic (such as benzyl cinnamate) for skin smoothing, and a topical skin irritant to increase...

20060045895 - Cosmetic composition comprising a polymer particle dispersion and a pigment dispersion: The present invention relates to a composition, especially a cosmetic composition, for caring for or making up the skin and/or integuments and/or the lips, which may be in the form of a cast product comprising a physiologically acceptable medium containing at least one liquid fatty phase, a colloidal dispersion of...

20060045892 - Cosmetic compositions: wherein R1 is selected from —OH and C1-C3 alkyl OH; and R2, R3, R4, R5 and R6 are independently selected from —H, —OH, C1-C6 alkyl, and C3-C6 cycloalkyl. The active material should contain no more than five —OH groups. Preferred active materials include 1,2-cyclohexanediol, 1,3-cyclohexanediol, 1,4-cyclohexanediol, 1,2,3-cyclohexanetriol, 1,3,5-cyclohexanetriol, and mixtures...

20060045893 - Long-wearing cosmetic compositions: A composition, a method for using said composition and a packaging system for said composition to significantly improve the appearance and feel of long wearing film-forming basecoats wherein said composition is a multi-layer cosmetic composition comprising: (a) a first composition, transfer-resistant, film-forming basecoat formulated to be applied to keratinous tissue...

20060045896 - Topical compositions comprising benfotiamine and pyridoxamine: The present invention provides a composition comprising an effective amount of benfotiamine and an effective amount of pyridoxamine in a suitable vehicle for topical application. The present compositions are useful in improving the appearance of aged skin characterized by wrinkles, loss of elasticity, and hyperpigmentation caused by chronoaging and/or photoaging...

20060045897 - Occlusive articles for wart treatment: An occlusive article is disclosed which functions to provide an occlusive or partially occlusive environment for the effective treatment of any wart where occlusive therapy may be practically administered....

20060045899 - Antimicrobial composition for medical articles: An antimicrobial composition is formed from about 30 to about 70 wt % of an antimicrobial formulation and about 30 to about 70 wt % of a polyurethane resin or polyurethane hybrids, copolymers, or mixtures with other polymers such as polyesters, nitrites, PVC, and synthetic rubber latexes. The antimicrobial formulation...

20060045898 - Weather resistant granular slug, snail and insect bait: The present invention is directed to a physical and chemical formulation designed to be attractive to, and eaten by, terrestrial mollusks, specifically slugs and snails. Optionally, the formulation is also attractive to and toxic to insects. Upon being eaten and after a set delay, the invention is designed to kill...

20060045900 - Embolization: Embolization and related methods are disclosed....

20060045904 - Joint therapy: A method for synergistically treating a joint of an animal, including introducing a cushioning agent into a joint; and introducing an enzyme or hormone adapted to stimulate cartilage production into the joint. The joint may be subjected to a compression regimen following injection of the cushioning agent and enzyme/hormone. Alternatively,...

20060045903 - Musculo-skeletal implant having a bioactive gradient: This invention relates to an implant for a musculoskeletal defect having a bioactive agent having a concentration gradient....

20060045902 - Polymeric wrap for in vivo delivery of osteoinductive formulations: The application discloses a polymeric wrap having one or more osteoinductive formulations, wherein each osteoinductive formulation comprises one or more osteoinductive agent(s). In one embodiment, the osteoinductive formulation(s) is contained within a biodegradable polymer sheet. In another embodiment of the invention, the polymeric wrap comprises at least two or more...

20060045901 - Stents with drug eluting coatings: The present invention relates generally to medical devices, preferably a stent, having a drug eluting surface coated or covered with a coating of particles comprising at least an outer layer, an inner layer, and a core comprising a therapeutic agent. Specifically, the invention relates to medical devices having a hydrophilic...

20060045905 - Composition for repressing transformation growth factor beta: A composition for repressing transformation growth factor β contains theanine as an active substance. The composition is useful for preventing or treating chronic glomerulonephritis, renal interstitial fibrosis, hepatic fibrosis, hepatic cirrhosis, idiopathic interstitial pneumonia, keloid, hidebound disease, arterial sclerosis, myocardial infarction, cardiac fibrosis, restenosis, acute megakaryoblastic leukemia, adult T-cell leukemia,...

20060045906 - Compositions and methods for activating protein synthesis and deactivating catabolic processes in skeletal muscle: A method for activating the protein synthesis machinery and deactivating catabolic processes within skeletal muscle by regulating molecular signals to control anabolic and anti-catabolic activity in skeletal muscle via nutrients including but not limited to amino acids and growth factors. Also provided is a supplemental dietary composition that may include...

20060045909 - Genome-based diet design: A method for providing nutrition for an animal by identifying a genome-based breed cluster to which the animal belongs and selecting a food for the animal having a nutritional formula matched at least in part to the nutritional needs of animals in the breed cluster. Optionally, the method further comprises...

20060045907 - Poultry feed containing plasma: The present invention relates to pelleted poultry feed containing plasma, and methods of making and using pelleted poultry feed containing plasma....

20060045908 - Ready-made supplementary feed for horses: Ready-made supplementary feed for horses that is also suited to prophylaxis or therapy of the muscle metabolism condition PSSM, contains 5-25 weight % rice meal and/or rice bran, 12-30 weight % supplying vegetable fat constituents, 20-40 weight % of green meal, 20-40 weight % of sugar beet seeds. The constituents...

20060045910 - Preserved fusogenic vesicles: Preserved fusogenic vesicles are disclosed that include a saccharide, a fusogen, and a first polar phospholipid that is a stable vesicle former. The preserved fusogenic vesicles have a fusion rate of at least 20 vesicle fusions per second when re-hydrated. Methods of preserving fusogenic vesicles also are disclosed. Unexpectedly, after...

20060045911 - Stable pharmaceutical formulations: A stable oral pharmaceutical formulation comprising ramipril or its pharmaceutically acceptable salt and a stabilizing amount of an ammoniomethacrylate copolymer in a pharmaceutically acceptable carrier medium is described....

20060045912 - 4-phenylbutyric acid controlled-release formulations for therapeutic use: Controlled-release formulations and dosage forms containing 4-phenylbutyric acid sodium salt, or other pharmaceutically acceptable salts, esters or prodrugs, and a controlled release material for use in the treatment of diseases and disorders including neoplastic disorders and neurodegenerative diseases The formulations provide extended release and extended half-life....

20060045913 - Controlled-release formulations containing tryptophan or its metabolites: New controlled-release formulations containing tryptophan and/or its metabolites are described, as well as the process to obtain them in tablet forms suitable for oral administration in the treatment of pathologies or conditions related to serotonin deficiency in the Nervous System. The formulations are comprised in double-layer tablets, one layer containing...

20060045914 - Matrix composition for stable microemulsions: A matrix composition for making a stable microemulsion for an active ingredient includes a C8-C18 N-alkyl pyrrolidone with little or no N-methyl pyrrolidone, and a water-insoluble organic solvent soluble therein, preferably more hydrophilic than said C8-C18 alkyl pyrrolidone and with low water solubility....

20060045917 - Method of conveying matter into targeted cells in a human body: A method of conveying matter to targeted cells in a human body, including the steps of providing a predetermined amount of substance desired to be conveyed to the human body, embracing the substance with a predetermined amount of carrier to form a nano-size dosage form and administrating the nano-size dosage...

20060045916 - Methods for producing silver nanoparticles: An exemplary embodiment of the invention is a method for making silver nanoparticles, and includes steps of reacting a silver salt with a phosphene amino acid to make silver nanoparticles. Exemplary phosphene amino acids include trimers, with a particular example being a trimeric amino acid conjugate containing one phosphene group....

20060045915 - Odor eliminating foot powder composition: A powder composition for eliminating foul odors associated with bromhidrosis and hyperhidrosis includes aluminum potassium sulfate in an amount of between 22% and 62% by weight, zinc oxide in an amount of between 8% and 36% by weight, and zinc undecylenate in an amount of between 6% and 34% by...

20060045918 - Homeopathic compositions and methods for the treatment of cancer: Provided are homeopathic compositions and methods for the preparation and use of such homeopathic compositions. Therapeutic methods comprise the administration of combinations of homeopathic compositions to provide the effective treatment of cancer, such as prostate cancers. Homeopathic compositions may be prepared by extracting from a patient a tissue sample comprising...

20060045919 - Homeopathic compositions and methods for the treatment of cancer: Provided are homeopathic compositions and methods for the preparation and use of such homeopathic compositions. Therapeutic methods comprise the administration of combinations of homeopathic compositions to provide the effective treatment of cancer, such as prostate cancers. Homeopathic compositions may be prepared by extracting from a patient a tissue sample comprising...

20060045920 - Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type ii and method of making same: Hydrolyzed collagen type II powder compositions for inducing cartilage formation in an individual, method of preparing the compositions and use of the compositions in treating connective tissue disorder, replenishing skin viscoelasticity. The compositions are administered through an orally ingestible delivery medium for absorption into the gastrointestinal tract. The compositions are...

20060045923 - Composition containing tinospora cordifolia and process for obtaining same: The present invention relates to a composition for use in a nutritional product, dietary supplement, food or pharmaceutical composition wherein such composition includes the plant Tinospora cordifolia or Tinospora cordifolia extract and is used to treat allergies, including but not limited to seasonal, perennial, or sporadic allergic rhinitis. The present...

20060045921 - Process to prepare a substance to eliminate the bacteria known as helicobacter pylori: A process for the production of a substance to eliminate the bacteria Helicobacter Pylori, involving boiling 3 (three) kilos of Cuachalalate (Amphipterygium adstringens) crust in sixteen (16) liters of water in a close express pan with a capacity of 21 (twenty-one) liters, for a period of 5 (five) hours, without...

20060045922 - Tumor and mutation suppressing plant extract: A compound derived from an extract of vegetative tissue of plants of the Genus Shortia demonstrates antitcarcinogenic potential by inhibiting the growth and development formation of tumors in living tissue in response to an organism known to cause the initiation of tumors in living tissue and by reducing mutation rates...

20060045924 - Dried fruit composition with laxative effects and method for administration thereof: A dried fruit composition enhanced with herbal extracts and a healthful dose of bacteria for enhanced laxative effects and appetite suppression. Preferred methods of manufacture and methods for oral administration of the dried fruit composition are further disclosed....

20060045925 - Pharmaceutical use of graptopetalum and related plants: The present invention relates to compositions comprising Graptopetalum and uses thereof Graptopetalum can protect animals from liver diseases and medical conditions, such as inflammation, steatosis, and fibrosis. In particular, Graptopetalum inhibits proliferation of activated hepatic stellate cells, which play a pivotal role in liver fibrosis. Graptopetalum also has anti-fibrosis activities...

20060045926 - Methods and compositions for enhancing collagen and proteoglycan synthesis in the skin: A composition for application to the skin can stimulate the in vivo synthesis of collagen and proteoglycans and improve the appearance of the skin, increasing its elasticity and fullness. In general, a composition according to the present invention comprises: (1) an antioxidant compound in a quantity sufficient to enhance collagen...

20060045928 - Composition containing herbal medicine component for promoting absorption and production method thereof: To make diacylglycerol obtained by adding an emulsifier contain both an effective oil-soluble component and an effective water-soluble component which are contained in herbal medicines, a herbal medicine component for promoting the absorption of the oil-soluble component in the small intestine and a production method thereof are objects of the...

20060045927 - Herbal formulations for modulating blood lipids: The present invention concerns herbal formulations for the modification of the levels of blood lipids. Aspects of the invention include the preparation of herbal formulations and methods for their use....

20060045929 - Functional food composition having effects of relieving alcohol-induced hangover symptoms and improving liver function: Disclosed is a functional food composition, which is effective in relieving alcohol-induced hangover symptoms and improving liver function. The composition includes 6-18% by dry weight of Polygonati Rhizoma, 10-40% by dry weight of Astragalus membranaceus Bge., 5-15% by dry weight of Artemisiae Scopariae Herba, 10-30% by dry weight of White...

20060045930 - Purified arabinogalactan-protein (agp) composition useful in the treatment psoriasis and other disorders: A purified Arabinogalactan-Protein (AGP) composition isolated through a selective method from the leaves and/or stems of Argemone mexicana plant is described. Also described is a purified Arabinogalactan-Protein (AGP) composition isolated from the leaves and/or stems of Argemone mexicana plant, which has one or more of the following effects: immunosuppression, lymphoproliferation...